AU741557B2

AU741557B2 - Mammalian secretory peptide-9

Info

Publication number: AU741557B2
Application number: AU82866/98A
Authority: AU
Inventors: Stephen R. Jaspers; Laura J Jelinek; Paul O Sheppard; Theodore E. Whitmore
Original assignee: Zymogenetics Inc
Current assignee: Zymogenetics Inc
Priority date: 1997-07-03
Filing date: 1998-07-02
Publication date: 2001-12-06
Anticipated expiration: 2018-07-02
Also published as: CA2294702A1; JP2002503112A; EP0998559A1; AU8286698A; WO1999001554A1; NZ502270A

Description

WO 99/01554 PCT/US98/13859 MAMMALIAN SECRETORY PEPTIDE 9 BACKGROUND OF THE INVENTION Proliferation and differentiation of cells of multicellular organisms are controlled by hormones and polypeptide growth factors. These diffusable molecules allow cells to communicate with each other and act in concert to form cells and organs, and to repair and regenerate damaged tissue. Examples of hormones and growth factors include the steroid hormones (e.g.

estrogen, testosterone), parathyroid hormone, follicle stimulating hormone, the interleukins, platelet derived growth factor (PDGF), epidermal growth factor (EGF), granulocyte-macrophage colony stimulating factor (GM-CSF), erythropoietin (EPO) and calcitonin.

Hormones and growth factors influence cellular metabolism by binding to proteins. Proteins may be integral membrane proteins that are linked to signaling pathways within the cell, such as second messenger systems. Other classes of proteins are soluble molecules, such as the transcription factors.

Thus, there is a continuing need to discover new hormones, growth factors and the like.

SUMMARY OF THE INVENTION The present invention addresses this need by providing a novel polypeptide and related compositions and methods. Within one aspect, the present invention provides WO 99/01554 PCTIUS98/13859 2 an isolated polynucleotide encoding a mammalian polypeptide termed secretory peptide 9, hereinafter -referred to as Zsig9. The mature human Zsig9 polypeptide is comprised of a sequence of amino acids approximately 64 amino acids long. Amino acid residue 21 of SEQ ID NO: 2, an arginine, is the initial amino acid of the mature polypeptide. Thus, it is believed that amino residues 1-20 comprise a signal sequence, and the mature Zsig9 polypeptide is represented by the amino acid sequence comprised of residues 21-84. The mature Zsig9 polypeptide is further represented by SEQ ID NO: 3. Within an additional embodiment, the polypeptide further comprises an affinity tag. Within a further embodiment, the polynucleotide is DNA.

Alternative forms of Zsig9 are defined by SEQ ID NOs: 4, 5, and 6. SEQ ID NO: 4 defines a processed form of Zsig9 in which the protein contains amino acid residues 23 84 of SEQ ID NO: 2.

SEQ ID NO: 5 represents another form of Zsig9 containing amino acid residues 23, a serine, to and including amino acid 47, a proline of SEQ ID NO: 2.

SEQ ID NO: 6 defines another processed form of Zsig9 contain amino acid residues 50, a threonine, to and including amino acid 84 of SEQ ID NO: 2.

SEQ ID NO: 16 and 17 represent another variant of Zsig9 and SEQ ID NO: 20 represents the mature sequence absent the first 20 amino acid residues, the signal sequence, of SEQ ID NO: 17.

SEQ ID NO: 18 and 19 represent the mouse ortholog of Zsig9; and SEQ ID NO: 21 depicts the .mature amino acid (11 WO 99/01554 PCT/US98/13859 3 sequence absent the first 20 amino acid residues, the signal sequence, of SEQ ID NO: 19.

Within a second aspect of the invention there is provided an expression vector comprising a transcription promoter; a DNA segment encoding a Zsig9 polypeptide as defined by SEQ ID NOs: 2-6, 17, 20 19 and 21 or a polypeptide 90% identical to said polypeptides, and a transcription terminator, wherein the promoter, DNA segment, and terminator are operably linked.

Within a third aspect of the invention there is provided a cultured eukaryotic cell into which has been introduced an expression vector as disclosed above, wherein said cell expresses a protein polypeptide encoded by the DNA segment.

Within a further aspect of the invention there is provided a chimeric polypeptide consisting essentially of a first portion and a second portion joined by a peptide bond. The first portion of the chimeric polypeptide consists essentially of a Zsig9 polypeptide as shown in SEQ ID NOs: 2-6, 17, 20 19 and 21(b) allelic variants of SEQ ID NOs: 2-6, 17, 20 19 and 21; and protein polypeptides that are at least 90% identical to or The second portion of the chimeric polypeptide consists essentially of another polypeptide such as an affinity tag. Within one embodiment the affinity tag is an immunoglobulin Fc polypeptide. The invention also provides expression vectors encoding the chimeric polypeptides and host cells transfected to produce the chimeric polypeptides.

Within an additional aspect of the invention there is provided an antibody that specifically binds to a Zsig9 polypeptide as disclosed above, and also an anti-idiotypic antibody which neutralizes the antibody to a Zsig9 polypeptide.

An additional embodiment of the present invention relates to a peptide or polypeptide which has the amino acid sequence of an epitope-bearing portion of a Zsig9 polypeptide having an amino acid sequence described above. Peptides or polypeptides having the amino acid sequence of an epitope-bearing portion of a Zsig9 polypeptide of the present invention include portions of such polypeptides with at least 30 to 50 amino acids, although epitope-bearing polypeptides of any length up to and including the entire amino acid sequence of a polypeptide of the present invention described above are also included in the present invention. An example of such a polypeptide is represented by SEQ ID NO:24.

Also claimed are antibodies which bind specifically to the above-defined Zsig9 polypeptides, methods for making said antibodies, and anti-idiotypic antibodies of said Zsig9-binding antibodies.

S i5 Accordingly, in a first embodiment of the present invention there is provided an isolated polynucleotide which encodes a mammalian polypeptide selected from the group a.

S.consisting of SEQ ID NOs:17, 19, 20 and 21 or a polypeptide which is at least identical to the polypeptides of said group.

According to a second embodiment of the present invention there is provided an 20 expression vector comprising the following operably linked elements: a transcription promoter; a polynucleotide which encodes a mammalian polypeptide selected fiom the group consisting of SEQ ID Nos:17, 19, 20 and 21 or a polypeptide which is at least identical to the polypeptides of said group; and a transcription terminator.

According to a third embodiment of the present invention there is provided a host cell into which has been introduced an expression vector according to the second embodiment.

According to a fourth embodiment of the present invention there is provided a method of producing a mammalian polypeptide selected from the group consisting of SEQ ID Nos:17, 19, 20 and 21' or a polypeptide which is at least 90% identical to the polypeptides of said group, the method comprising culturing the host cell of the third embodiment under conditions conducive to expression of said polypeptide and isolating S said expressed polypeptide.

I B ZZ04 93.doc: n ir 4a According to a fifth embodiment of the present invention there is provided a mammalian polypeptide selected from the group consisting of SEQ ID Nos:17, 19, 20 and 21 or a polypeptide which is at least 90% identical to the polypeptides of said group produced according to the method of the fourth embodiment.

According to a sixth embodiment of the present invention there is provided an isolated polypeptide selected from the group of amino acid sequences consisting of SEQ ID NOs:2-6 or a polypeptide which is at least 90% identical to said polypeptides.

According to a seventh embodiment of the present invention there is provided an isolated polypeptide selected from the group of amino acid sequences consisting of SEQ ID NOs:17, 20, 19 and 21 or a polypeptide which is at least 90% identical to said polypeptides.

According to an eighth embodiment of the present invention there is provided a pharmaceutical composition comprising a polypeptide according to any one of the fifth to seventh embodiments together with a pharmaceutically acceptable vehicle.

i According to a ninth embodiment of the present invention there is provided a chimeric polypeptide consisting essentially of a first portion and a second portion joined by a peptide bound, the first portion consisting essentially of a Zsig9 polypeptide as shown in SEQ ID NOs:2-6, 17, 20, 19 and 21 allelic variants of SEQ ID NOs:2-6, 17, 19 and 21; and protein polypeptides that are at least 90% identical to or and 20 the second portion comprising an affinity tag.

According to a tenth embodiment of the present invention there is provided an isolated antibody, antibody fragment or single-chain antibody that specifically binds to a mammalian polypeptide, said polypeptide being defined by the amino acid sequences of SEQ ID NOs:2-6.

According to an eleventh embodiment of the present invention there is provided an isolated antibody, antibody fragment or single-chain antibody that specifically binds to a mammalian polypeptide, said polypeptide being defined by the amino acid sequences of SEQ ID NOs:17, 20, 19 and 21.

According to a twelfth embodiment of the present invention there is provided a pharmaceutical composition comprising an antibody, antibody fragment or single-chain antibody of the tenth or eleventh embodiment, together with a pharmaceutically acceptable vehicle.

According to a thirteenth embodiment of the present invention there is provided the use of an antibody, antibody fragment or single chain antibody according to the tenth or S eleventh embodiments to produce an anti-idiotypic antibody.

A [R:\LIBZZ]04193.doc:mrr 4b According to a fourteenth embodiment of the present invention there is provided an anti-idiotypic antibody produced according to the thirteenth embodiment.

According to a fifteenth embodiment of the present invention there is provided a pharmaceutical composition comprising an anti-idiotypic antibody of the fourteenth embodiment together with a pharmaceutically acceptable carrier.

According to a sixteenth embodiment of the present invention there is provided a method for producing an antibody which binds to a mammalian polypeptide or a peptide or polypeptide defined by SEQ ID NOs:2-6 or to a peptide or polypeptide which is at least 90% identical to said peptide or polypeptide comprising bringing into contact a polypeptide defined by SEQ ID NOs:2-6 or a peptide or polypeptide which is at least identical to said peptide or polypeptide with a cell capable of producing antibodies or the cell is brought into contact with a nucleic acid which encodes said peptide or polypeptide, wherein said cell produces antibodies to said peptide or polypeptide; and isolating said antibody.

is According to a seventeenth embodiment of the present invention there is provided a method for producing an antibody which binds to a polypeptide defined by SEQ ID S. NOs: 17, 19, 20 or 21 or to a peptide or polypeptide which is at least 90% identical to said peptide or polypeptide comprising bringing into contact a polypeptide defined by SEQ ID NOs:17, 20, 19 and 21 or a peptide or polypeptide which is at least 90% identical to said peptide or polypeptide with a cell capable of producing antibodies or the cell is brought 9 into contact with a nucleic acid which encodes said peptide or polypeptide, wherein said cell produces antibodies to said peptide or polypeptide; and ***990 9 isolating said antibody.

According to an eighteenth embodiment of the present invention there is provided an antibody produced by the method according to the sixteenth or seventeenth embodiment.

According to a nineteenth embodiment of the present invention there is provided a pharmaceutical composition comprising the antibody of the eighteenth embodiment together with a pharmaceutically acceptable vehicle.

These and other aspects of the invention will become evidence upon reference to the following detailed description.

I BZZ]04 I 93.cioc: nirr 4c Detailed Description of the Invention The teachings of all of the references cited herein are incorporated in their entirety herein by reference.

The tei-rn "ortholog" (or "species homolog") denotes a polypeptide or protein obtained from one species that has 9 9 90 9. 9 9* .9 0 99 0 0 0 0 00 0 0000 0 0 0000 0009 0 0090 00000 0 9000 0 9000 000000 0 R AL 1 13 ZZ104 193A doc: nir WO 99/01554 PCTIUS98/13859 homology to an analogous polypeptide or protein from a different species.

The term "paralog" denotes a polypeptide or protein obtained from a given species that has homology to a distinct polypeptide or protein from that same species.

The term "allelic variant" denotes any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in phenotypic polymorphism within populations. Gene mutations can be silent no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequence. The term allelic variant is also used herein to denote a protein encoded by an allelic variant of a gene.

The term "expression vector" denotes a DNA molecule, linear or circular, that comprises a segment encoding a polypeptide of interest operably linked to additional segments that provide for its transcription. Such additional segments include promoter and terminator sequences, and may optionally include one or more origins of replication, one or more selectable markers, an enhancer, a polyadenylation signal and the like.

Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both.

The term "isolated", when applied to a polynucleotide, denotes that the polynucleotide has been removed from its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that are separated from their natural environment and include cDNA and genomic clones. Isolated DNA WO 99/01554 PCT/US98/13859 6 molecules of the present invention are free of other genes with which they are ordinarily associated, but may include -naturally occurring 5' and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art, Dynan and Tijan, Nature 316:774-78 (1985). When applied to a protein, the term "isolated" indicates that the protein is found in a condition other than its native environment, such as apart from blood and animal tissue. In a preferred form, the isolated protein is substantially free of other proteins, particularly other proteins of animal origin. It is preferred to provide the protein in a highly purified form, i.e., greater than 95% pure, more preferably greater than 99% pure.

The term "operably linked", when referring to DNA segments, denotes that the segments are arranged so that they function in concert for their intended purposes, e.g.

transcription initiates in the promoter and proceeds through the coding segment to the terminator.

The term "polynucleotide" is a single- -or doublestranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. Polynucleotides include RNA and DNA, and may be isolated from natural sources, synthesized in vitro, or prepared from a combination of natural and synthetic molecules.

The term "complements of polynucleotide molecules" denotes polynucleotide molecules having a complementary base sequence and reverse orientation as compared to a reference sequence.

The term "degenerate nucleotide sequence" denotes a sequence of nucleotides that includes one or more WO 99/01554 PCT/US98/13859 7 degenerate codons (as compared to.a reference polynucleotide molecule that encodes a polypeptide).

-Degenerate codons contain different triplets of nucleotides, but encode the same amino acid residue GAU and GAC triplets each encode Asp).

The term "promoter" denotes a portion of a gene containing DNA sequences that provide for the binding of RNA polymerase and initiation of transcription. Promoter sequences are commonly, but not always, found in the non-coding regions of genes.

The term "secretory signal sequence" denotes a DNA sequence that encodes a polypeptide (a "secretory peptide") that, as a component of a larger polypeptide, directs the larger polypeptide through a secretory pathway of a cell in which it is synthesized. The larger peptide is commonly cleaved to remove the secretory peptide during transit through the secretory pathway.

The term "receptor" denotes a cell-associated protein that binds to a bioactive molecule a ligand) and mediates the effect of the ligand on the cell. Membranebound receptors are characterized by a multi-domain structure comprising an extracellular ligand-binding domain and an intracellular effector domain that is typically involved in signal transduction. Binding of ligand to receptor results in a conformational change in the receptor that causes an interaction between the effector domain and other molecule(s) in the cell. This interaction in turn leads to an alteration in the metabolism of the cell. Metabolic events that are linked to receptor-ligand interactions include gene transcription, phosphorylation, dephosphorylation, increases in cyclic AMP production, mobilization of cellular calcium, mobilization of membrane lipids, cell WO 99/01554 PCT/US98/13859 8 adhesion, hydrolysis of inositol lipids and hydrolysis of phospholipids. Most nuclear receptors also exhibit a multi-domain structure, including an amino-terminal, transactivating domain, a DNA binding domain and a ligand binding domain. In general, receptors can be membrane bound, cytosolic or nuclear; monomeric thyroid stimulating hormone receptor, beta-adrenergic receptor) or multimeric PDGF receptor, growth hormone receptor, IL-3 receptor, GM-CSF receptor, G-CSF receptor, erythropoietin receptor and IL-6 receptor).

The term "complement/anti-complement pair" denotes non-identical moieties that form a non-covalently associated, stable pair under appropriate conditions. For instance, biotin and avidin (or streptavidin) are prototypical members of a complement/anti-complement pair.

Other exemplary complement/anti-complement pairs include receptor/ligand pairs, antibody/antigen (or hapten or epitope) pairs, sense/antisense polynucleotide pairs, and the like. Where subsequent dissociation of the complement/anti-complement pair is desirable, the complement/anti-complement pair preferably has a binding affinity of <109 M 1 A "soluble protein" is a protein polypeptide that is not bound to a cell.membrane.

Within preferred embodiments of the invention the isolated polynucleotides will hybridize to similar sized regions of polynucleotide defined by SEQ ID NO:1, or a sequence complementary thereto, under stringent conditions. In general, stringent conditions are selected to be about 5°C lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic WO 99/01554 PCT/US98/13859 9 strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typical stringent conditions are those in which the salt concentration is about 0.02 M or less at pH 7 and the temperature is at least about 60 0 C. As previously noted, the isolated polynucleotides of the present invention include DNA and RNA. Methods for isolating DNA and RNA are well known in the art. Total RNA can be prepared using guanidine HC1 extraction followed by isolation by centrifugation in a CsCl gradient, Chirgwin et al., Biochemistry 18:52-94 (1979). Poly RNA is prepared from total RNA using the method of Aviv and Leder, Proc.

Natl. Acad. Sci. USA 69:1408-1412 (1972). Complementary DNA (cDNA) is prepared from poly(A)+ RNA using known methods. Polynucleotides encoding Zsig9 polypeptides are then identified and isolated by, for example, hybridization or PCR.

The present invention further provides counterpart polypeptides and polynucleotides from other species (orthologs or paralogs). Of particular interest are Zsig9 polypeptides from other mammalian species, including murine, rat, porcine, ovine, bovine, canine, feline, equine and other primate proteins. Species homologs of the human proteins can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the protein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue of cell line. A Zsig9-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human cDNA or with one WO 99/01554 PCT/US98/13859 or more sets of degenerate probes.based on the disclosed sequences. A cDNA can also be cloned using the polymerase -chain reaction, or PCR (Mullis, U.S. Patent 4,683,202), using primers designed from the sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to Zsig9. Similar techniques can also be applied to the isolation of genomic clones.

Those skilled in the art will recognize that the sequences disclosed in SEQ ID NOs:l and 2, SEQ ID NOs:16 and 17, SEQ ID NOs. 18 and 19, represent a specific alleles of the human Zsig9 gene and polypeptide, and that allelic variation and alternative splicing are expected to occur. Allelic variants can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures. Allelic variants of the DNA sequence shown in SEQ ID NO: 1, including those containing silent mutations and those in which mutations result in amino acid sequence changes, are within the scope of the present invention, as are proteins which are allelic variants of SEQ ID NOs: 3, 4, 5, and 6.

Additionally, the polynucleotides of the present invention can be synthesized using DNA synthesizers.

Currently the method of choice is the phosphoramidite method. Each complementary strand of a double stranded DNA of gene or a gene fragment is made separately. The production of short DNA fragments (60 to 80 bp) can be accomplished by synthesizing the complementary strands and then annealing them. For the production of longer DNA molecules the coupling efficiency of each cycle during chemical DNA synthesis is seldom 100%. To overcome this problem, synthetic genes (double-stranded) are assembled WO 99/01554 PCT/US98/13859 11 in modular form from single-stranded fragments that are from 20 to 100 nucleotides in length.

One method for building a synthetic gene requires the initial production of a set of overlapping, complementary oligonucleotides, each of which is between 20 to nucleotides long. The sequences of the strands are planned so that, after annealing, the two end segments of the gene are aligned to give blunt ends. Each internal section of the gene has complementary 3' and 5' terminal extensions that are designed to base pair precisely with an adjacent section. Thus, after the gene is assembled, .the only remaining requirement to complete the process is sealing the nicks along the backbones of the two strands with T4 DNA ligase. In addition to the protein coding sequence, synthetic genes can be designed with terminal sequences that facilitate insertion into a restriction endonuclease sites of a cloning vector and other sequences should also be added that contain signals for the proper initiation and termination of transcription and translation. See Glick, Bernard R. and Jack J. Pasternak, Molecular Biotechnology, Principles Applications of Recombinant DNA, (ASM Press, Washington, D.C. 1994), Itakura, K. et al.

Synthesis and use of synthetic oligonucleotides. Annu.

Rev. Biochem. 53 323-356 (1984), and Climie, S. et al.

Chemical synthesis of the thymidylate synthase gene. Proc.

Natl. Acad. Sci. USA 87 :633-637 (1990).

Those skilled in the art will recognize that the sequences disclosed in SEQ ID NOS:1, 2, 3, 4, 5, and 6 represent a single allele of the human. Allelic variants of these sequences can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures.

WO 99/01554 PCT/US98/13859 12 The present invention further provides counterpart proteins and polynucleotides from other species ("species -orthologs"). Of particular interest are Zsig9 polypeptides from other mammalian species, including murine, porcine, ovine, bovine, canine, feline, equine, and other primates. Species orthologs of the human Zsig9 protein can be cloned using information and compositions provided by the present invention in combination with conventional cloning techniques. For example, a cDNA can be cloned using mRNA obtained from a tissue or cell type that expresses the protein. Suitable sources of mRNA can be identified by probing Northern blots with probes designed from the sequences disclosed herein. A library is then prepared from mRNA of a positive tissue or cell line. A protein-encoding cDNA can then be isolated by a variety of methods, such as by probing with a complete or partial human or mouse cDNA or with one or more sets of degenerate probes based on the disclosed sequences.

A

cDNA can also be cloned using the polymerase chain reaction, or PCR (Mullis, U.S. Patent No. 4,683,202), using primers designed from the sequences disclosed herein. Within an additional method, the cDNA library can be used to transform or transfect host cells, and expression of the cDNA of interest can be detected with an antibody to the protein. Similar techniques can also be applied to the isolation of genomic clones. As used and claimed the language "an isolated polynucleotide which encodes a polypeptide, said polypeptide being defined by SEQ ID NO: 2-6, 17, 20 19 and 21" includes all allelic variants and species orthologs of the polypeptide of SEQ ID NOs: 2-6, 17, 20 19 and 21.

The present invention also provides isolated protein polypeptides that are substantially homologous to the polypeptides of SEQ ID NOs: 2, 3, 4, 5 or 6 and their species orthologs. By "isolated" is meant a protein or WO 99/01554 PCT/US98/13859 13 polypeptide that is found in a condition other than its native environment, such as apart from blood and animal -tissue. In a preferred form, the isolated polypeptide is substantially free of other polypeptides, particularly other polypeptides of animal origin. It is preferred to provide the polypeptides in a highly purified form, i.e.

greater than 95% pure, more preferably greater than 99% pure. The term "substantially homologous" is used herein to denote polypeptides having 50%, preferably 60%, more preferably at least 80%, sequence identity to the sequence shown in SEQ ID NO:2,or its species orthologs. Such polypeptides will more preferably be at least identical, and most preferably 95% or more identical to SEQ ID NO:3,or its species orthologs. Percent sequence identity is determined by conventional methods. See, for example, Altschul et al., Bull. Math. Bio. 48: 603-616 (1986) and Henikoff and Henikoff, Proc. Natl. Acad. Sci.

USA 89:10915-10919 (1992). Briefly, two amino acid sequences are aligned to optimize the alignment scores using a gap opening penalty of 10, a gap extension penalty of 1, and the "blossom 62" scoring matrix of Henikoff and Henikoff (ibid.) as shown in Table 2 (amino acids are indicated by the standard one-letter codes) The percent identity is then calculated as: Total number of identical matches x 100 [length of the longer sequence plus the number of gaps introduced into the longer sequence in order to align the two sequences] Table 1 "0 A R N D C Q E G H I L K M F P S T W Y V A 4 R -1 N -2 0 6 D -2 -2 1 6 C 0 -3 -3 -3 9 Q -1 1 0 0 -3 E -1 0 0 2 -4 2 G 0 -2 0 -1 -3 -2 -2 6 H -2 0 1 -1 -3 0 0 -2 8 I -1 -3 -3 -3 -1 -3 -3 -4 -3 4 L -1 -2 -3 -4 -1 -2 -3 -4 -3 2 4 K -1 2 0 -1 -3 1 1 -2 -1 -3 -2 M -1 -1 -2 -3 -1 0 -2 -3 -2 1 2 -1 F -2 -3 -3 -3 -2 -3 -3 -3 -1 0 0 -3 0 6 P -1 -2 -2 -1 -3 -1 -1 -2 -2 -3 -3 -1 -2 -4 7 S 1 -1 1 0 -1 0 0 0 -1 -2 -2 0 -1 -2 -1 4 T 6 -1 0 -1 -1 -1 -1 -2 -2 -1 -1 -1 -1 -2 -1 1 W -3 -3 -4 -4 -2 -2 -3 -2 -2 -3 -2 -3 -1 1 -4 -3 -2 11 Y -2 -2 -2 -3 -2 -1 -2 -3 2 -1 -1 -2 -1 3 -3 -2 -2 2 7 V 0 -3 -3 -3 -1 -2 -2 -3 -3 3 1 -2 1 -1 -2 -2 0 -3 -1 4 WO 99/01554 PCT/US98/13859 Sequence identity of polynucleotide molecules is determined by similar methods using a ratio as disclosed -above.

Substantially homologous proteins and polypeptides are characterized as having one or more amino acid substitutions, deletions or additions. These changes are preferably of a minor nature, that is conservative amino acid substitutions (see Table 3) and other substitutions that do not significantly affect the folding or activity of the protein or polypeptide; small deletions, typically of one to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or a small extension that facilitates purification (an affinity tag), such as a poly-histidine tract, protein A, Nilsson et al., EMBO J. 4:1075, (1985); Nilsson et al., Methods Enzymol. 198:3, (1991), glutathione S transferase, Smith and Johnson, Gene 67:31, (1988), or other antigenic epitope or binding domain.

See, in general Ford et al., Protein Expression and Purification 2: 95-107, (1991). DNAs encoding affinity tags are available from commercial suppliers Pharmacia Biotech, Piscataway, NJ).

Table 2 Conservative amino acid substitutions Basic: arginine lysine histidine Acidic: glutamic acid aspartic acid Polar: glutamine asparagine Hydrophobic: leucine WO 99/01554 PCT/US98/13859 16 Table 2, continued isoleucine valine Aromatic: phenylalanine tryptophan tyrosine Small: glycine alanine serine threonine methionine The proteins of the present invention can also comprise, in addition to the 20 standard amino acids, nonnaturally occurring amino acid residues. Non-naturally occurring amino acids include, without limitation, trans- 3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline, trans-4-hydroxyproline, N-methyl-glycine, allo-threonine, methylthreonine, hydroxyethyl-cysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, tert-leucine, norvaline, 2azaphenylalanine, 3-azaphenylalanine, 4-azaphenyl-alanine, 4-fluorophenylalanine, 4-hydroxyproline, 6-N-methyl lysine, 2-aminoisobutyric acid, isovaline and a-methyl serine. Several methods are known in the art for incorporating non-naturally occurring amino acid residues into proteins. For example, an in vitro system can be employed wherein nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNA are known in the art. Transcription and translation of plasmids containing nonsense mutations are carried out in a cell free system comprising an E. coli S30 extract and commercially available enzymes and other reagents.

WO 99/01554 PCT/US98/13859 17 Proteins are purified by chromatography. See, for example, Robertson et al., J. Am. Chem. Soc. 113:2722 (1991); Ellman et al., Meth. Enzymol. 202:301 (1991); Chung et al., Science 259:806-09 (1993); and Chung et al., Proc. Natl. Acad. Sci. USA 90:10145-49 (1993). -In a second method, translation is carried out in Xenopus oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNAs (Turcatti et al., J. Biol.

Chem. 271:19991-98 (1996). Within a third method, E. coli cells are cultured in the absence of a natural amino acid that is to be replaced phenylalanine)' and in the presence of the desired non-naturally occurring amino acid(s) 2-azaphenylalanine, 3-azaphenylalanine, 4azaphenylalanine, or 4-fluorophenylalanine). The nonnaturally occurring amino acid is incorporated into the protein in place of its natural counterpart. See, Koide et al., Biochem. 33:7470-76, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by in vitro chemical modification.

Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403 (1993).

A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, nonnaturally occurring amino acids, and unnatural amino acids may be substituted for Zsig9* amino acid residues.

"Unnatural amino acids" have been modified after protein synthesis, and/or have a chemical structure in their side chain(s) different from that of the standard amino acids.

Unnatural amino acids can be chemically synthesized, or preferably, are commercially available, and include pipecolic acid, thiazolidine carboxylic acid, WO 99/01554 PCT/US98/13859 18 dehydroproline, 3- and 4-methylproline, and 3,3dimethylproline.

Essential amino acids in the polypeptides of the present invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine-scanning mutagenesis, Cunningham and Wells, Science 244, 1081-1085, (1989); Bass et al., Proc. Natl. Acad. Sci. USA 88:4498-4502, (1991). In the latter technique, single alanine mutations are introduced at every residue in the molecule, and the resultant mutant molecules are tested for biological activity ligand binding and signal transduction) to identify amino acid residues that are critical to the activity of the molecule. Sites of ligand-protein interaction can also be determined by analysis of crystal structure as determined by such techniques as nuclear magnetic resonance, crystallography or photoaffinity labeling. See, for example, de Vos et al., Science 255:306-312, (1992); Smith et al., J. Mol. Biol. 224:899-904, (1992); Wlodaver et al., FEBS Lett. 309:59-64, (1992). The identities of essential amino acids can also be inferred from analysis of homologies with related proteins.

Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer, Science 241:53-57, (1988) or Bowie and Sauer, Proc. Natl.

Acad. Sci. USA 86:2152-2156, (1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions in a polypeptide, selecting for functional polypeptide, and then sequencing the mutagenized polypeptides to determine the spectrum of allowable substitutions at each position. Other methods that can be used include phage display, Lowman et WO 99/01554 PCT/US98/13859 19 al., Biochem. 30:10832-10837, (1991); Ladner et al., U.S.

Patent No. 5,223,409; Huse, WIPO Publication WO 92/06204, and region-directed mutagenesis, Derbyshire et al., Gene 46:145, (1986); Ner et al., DNA 7:127, (1988) Mutagenesis methods as disclosed above can be combined with high-throughput screening methods to detect activity of cloned, mutagenized proteins in host cells.

Preferred assays in this regard include cell proliferation assays and biosensor-based ligand-binding assays, which are described below. Mutagenized DNA molecules that encode active proteins or portions thereof ligand-binding fragments) can be recovered from the host cells and rapidly sequenced using modern equipment. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide of interest, and can be applied to polypeptides of unknown structure.

Using the methods discussed above, one of ordinary skill in the art can prepare a variety of polypeptides that are substantially homologous to SEQ ID NO:2 or allelic variants thereof and retain the properties of the wild-type protein. As expressed and claimed herein the language, "a polypeptide as defined by SEQ ID NO: 2" includes all allelic variants and species orthologs of the polypeptide.

The protein/polypeptides of the present invention, including full-length proteins, protein fragments (e.g.

ligand-binding fragments), and fusion polypeptides can be produced in genetically engineered host cells according to conventional techniques. Suitable host cells are those cell types that can be transformed or transfected with exogenous DNA and grown in culture, and include bacteria, fungal cells, and cultured higher eukaryotic cells.

WO 99/01554 PCT/US98/13859 Eukaryotic cells, particularly cultured cells of multicellular organisms, are preferred. Techniques for manipulating cloned DNA molecules and introducing exogenous DNA into a variety of host cells are disclosed by Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989), and Ausubel et al., ibid.

In general, a DNA sequence encoding a Zsig9 polypeptide is operably linked to other genetic elements required for its expression, generally including a transcription promoter and terminator, within an expression vector. The vector will also commonly contain one or more selectable markers and one or more origins of replication, although those skilled in the art will recognize that within certain systems selectable markers may be provided on separate vectors, and replication of the exogenous DNA may be provided by integration into the host cell genome. Selection of promoters, terminators, selectable markers, vectors and other elements is a matter of routine design within the level of ordinary skill in the art. Many such elements are described in the literature and are available through commercial suppliers.

To direct a Zsig9 polypeptide into the secretory pathway of a host cell, a secretory signal sequence (also known as a leader sequence, prepro sequence or pre sequence) is provided in the expression vector. The secretory signal sequence may be that of the protein, or may be derived from another secreted protein t-PA) or synthesized de novo. The secretory signal sequence is joined to the Zsig9 DNA sequence in the correct reading frame. Secretory signal sequences are commonly positioned to the DNA sequence encoding the polypeptide of interest, although certain signal sequences may be positioned elsewhere in the DNA sequence of interest (see, WO 99/01554 PCT/US98/13859 21 Welch et al., U.S. Patent No. 5,037,743; Holland et al., U.S. Patent No. 5,143,830).

Cultured mammalian cells are preferred hosts within the present invention. Methods for introducing exogenous DNA into mammalian host cells include calcium phosphatemediated transfection, Wigler et al., Cell 14:725, (1978); Corsaro and Pearson, Somatic Cell Genetics 7:603, (1981): Graham and Van der Eb, Virology 52:456, (1973), electroporation, Neumann et al., EMBO J. 1:841-845, (1982), DEAE-dextran mediated transfection, "Ausubel et al., eds., Current Protocols in Molecular Biology, John Wiley and Sons, Inc., NY, (1987), and liposome-mediated transfection, Hawley-Nelson et al., Focus 15:73, (1993); Ciccarone et al., Focus 15:80, (1993). The production of recombinant polypeptides in cultured mammalian cells is disclosed, for example, by Levinson et al., U.S. Patent No. 4,713,339; Hagen et al., U.S. Patent No. 4,784,950; Palmiter et al., U.S. Patent No. 4,579,821; and Ringold, U.S. Patent No. 4,656,134. Suitable cultured mammalian cells include the COS-1 (ATCC No. CRL 1650),-COS-7 (ATCC No. CRL 1651), BHK (ATCC No. CRL 1632), BHK 570 (ATCC No.

CRL 10314), 293, ATCC No. CRL 1573; Graham et al., J. Gen.

Virol. 36:59-72, (1977) and Chinese hamster ovary (e.g.

CHO-K1; ATCC No. CCL 61) cell lines. Additional suitable cell lines are known in the art and available from public depositories such as the American Type Culture Collection, Rockville, Maryland. In general, strong transcription promoters are preferred, such as promoters from SV-40 or cytomegalovirus. See, U.S. Patent No. 4,956,288.

Other suitable promoters include those from metallothionein genes Patent Nos. 4,579,821 and 4,601,978,and the adenovirus major late promoter.

WO 99/01554 PCTIUS98/13859 22 Drug selection is generally used to select for -cultured mammalian cells into which foreign DNA has been inserted. Such cells are commonly referred to as "transfectants". Cells that have been cultured in the presence of the selective agent and are able to pass the gene of interest to their progeny are referred to as "stable transfectants." A preferred selectable marker is a gene encoding resistance to the antibiotic neomycin.

Selection is carried out in the presence of a neomycintype drug, such as G-418 or the like. Selection systems may also be used to increase the expression.level of the gene of interest, a process referred to as "amplification." Amplification is carried out by culturing transfectants in the presence of a low level of the selective agent and then increasing the amount of selective agent to select for cells that produce high levels of the products of the introduced genes. A preferred amplifiable selectable marker is dihydrofolate reductase, which confers resistance to methotrexate.

Other drug resistance genes hygromycin resistance, multi-drug resistance, puromycin acetyltransferase) can also be used.

Other higher eukaryotic cells can also be used as hosts, including insect cells, plant cells and avian cells. Transformation of insect cells and production of foreign polypeptides therein is disclosed by Guarino et al., U.S. Patent No. 5,162,222; Bang et al., U.S. Patent No. 4,775,624; and WIPO publication WO 94/06463. The use of Agrobacterium rhizogenes as a vector for expressing genes in plant cells has been reviewed by Sinkar et al., J. Biosci. (Bangalore) 11:47-58, (1987).

WO 99/01554 PCT/US98/13859 23 Fungal cells, including yeast cells, and particularly cells of the genus Saccharomyces, can also be used within -the present invention, such as for producing protein fragments or polypeptide fusions. Methods for transforming yeast cells with exogenous DNA and producing recombinant polypeptides therefrom are disclosed by, for example, Kawasaki, U.S. Patent No. 4,599,311; Kawasaki et al., U.S. Patent No. 4,931,373; Brake, U.S. Patent No.

4,870,008; Welch et al., U.S. Patent No. 5,037,743; and Murray et al., U.S. Patent No. 4,845,075. Transformed cells are selected by phenotype determined by the selectable marker, commonly drug resistance or the ability to grow in the absence of a particular nutrient leucine). A preferred vector system for use in yeast is the POT1 vector system disclosed by Kawasaki et al. (U.S.

Patent No. 4,931,373), which allows transformed cells to be selected by growth in glucose-containing media.

Suitable promoters and terminators for use in yeast include those from glycolytic enzyme genes (see, e.g., Kawasaki, U.S. Patent No. 4,599,311; Kingsman et al., U.S.

Patent No. 4,615,974; and Bitter, U.S. Patent No.

4,977,092) and alcohol dehydrogenase genes._ See also U.S.

Patents Nos. 4,990,446; 5,063,154; 5,139,936 and 4,661,454. Transformation systems for other yeasts, including Hansenula polymorpha, Schizosaccharomyces pombe, Kluyveromyces lactis, Kluyveromyces fragilis, Ustilago maydis, Pichia pastoris, Pichia methanolica, Pichia guillermondii and Candida maltosa are known in the art.

See, for example, Gleeson et al., J. Gen. Microbiol.

132:3459-3465, (1986) and Cregg, U.S. Patent No.

4,882,279.

Aspergillus cells may be utilized according to the methods of McKnight et al., U.S. Patent No. 4,935,349.

WO 99/01554 PCT/US98/13859 24 Methods for transforming Acremonium chrysogenum are disclosed by Sumino et al., U.S. Patent No. 5,162,228.

Methods for transforming Neurospora are disclosed by Lambowitz, U.S. Patent No. 4,486,533.

Transformed or transfected host cells are cultured according to conventional procedures in a culture medium containing nutrients and other components required for the growth of the chosen host cells. A variety of suitable media, including defined media and complex media, are known in the art and generally include a carbon source, a nitrogen source, essential amino acids, vitamins and minerals. Media may also contain such components as growth factors or serum, as required. The growth medium will generally select for cells containing the exogenously added DNA by, for example, drug selection or deficiency in an essential nutrient which is complemented by the selectable marker carried on the expression vector or cotransfected into the host cell.

Within one aspect of the present invention, a novel protein is produced by a cultured cell, and the cell is used to screen for a receptor or receptors for the protein, including the natural receptor, as well as agonists and antagonists of the natural ligand.

Proteins of the present invention are useful for enhancing the growth or development of the placenta, heart, and liver. Zsig9 can be measured in vitro using cultured cells or in vivo by administering molecules of the claimed invention to the appropriate animal model.

For instance, Zsig9 transfected (or co-transfected) expression host cells may be embedded in an alginate environment and injected (implanted) into recipient animals. Alginate-poly-L-lysine microencapsulation, permselective membrane encapsulation and diffusion WO 99/01554 PCT/US98/13859 chambers have been described as a means to entrap transfected mammalian cells or primary mammalian cells.

These types of non-immunogenic "encapsulations" or microenvironments permit the transfer of nutrients into the microenvironment, and also permit the diffusion of proteins and other macromolecules secreted or released by the captured cells across the environmental barrier to the recipient animal. Most importantly, the capsules or microenvironments mask and shield the foreign, embedded cells from the recipient animal's immune response. Such microenvironments can extend the life of the injected cells from a few hours or days (naked cells).to several weeks (embedded cells).

Alginate threads provide a simple and quick means for generating embedded cells. The materials needed to generate the alginate threads are readily available and relatively inexpensive. Once made, the alginate threads are relatively strong and durable, both in vitro and, based on data obtained using the threads, in vivo. The alginate threads are easily manipulable and the methodology is scaleable for preparation of numerous threads. In an exemplary procedure, 3% alginate is prepared in sterile H20, and sterile filtered. Just prior to preparation of alginate threads, the alginate solution is again filtered. An approximately 50% cell suspension (containing about 5 x 10 s to about 5 x 107 cells/ml) is mixed with the 3% alginate solution. One ml of the alginate/cell suspension is extruded into a 100 mM sterile filtered CaC1, solution over a time period of ~15 min, forming a "thread". The extruded thread is then transferred into a solution of 50 mM CaC12, and then into a solution of 25 mM CaCl 2 The thread is then rinsed with deionized water before coating the thread by incubating in a 0.01% solution of poly-L-lysine. Finally, the thread is rinsed with Lactated Ringer's Solution and drawn from WO 99/01554 PCT/US98/13859 26 solution into a syringe barrel (without needle attached).

A large bore needle is then attached to the syringe, and -the thread is intraperitoneally injected into a recipient in a minimal volume of the Lactated Ringer's Solution.

An alternative in vivo approach for assaying proteins of the present invention involves viral delivery systems.

Exemplary viruses for this purpose include adenovirus, herpesvirus, vaccinia virus and adeno-associated virus (AAV). Adenovirus, a double-stranded DNA virus, is currently the best studied gene transfer vector for delivery of heterologous nucleic acid (for a review, see T.C. Becker et al., Meth. Cell Biol. 43:161-89 (1994); and J.T. Douglas and D.T. Curiel, Science Medicine 4:44-53 (1997). The adenovirus system offers several advantages: adenovirus can accommodate relatively large DNA inserts; (ii) be grown to high-titer; (iii) infect a broad range of mammalian cell types; and (iv) be used with a large number of available vectors containing different promoters. Also, because adenoviruses are stable in the bloodstream, they can be administered by intravenous injection. Some disadvantages (especially for gene therapy) associated with adenovirus gene delivery include: very low efficiency integration into the host genome; (ii) existence in primarily episomal form; and (iii) the host immune response to the administered virus, precluding readministration of the adenoviral vector.

By deleting portions of the adenovirus genome, larger inserts (up to 7 kb) of heterologous DNA can be accommodated. These inserts may be incorporated into the viral DNA by direct ligation or by homologous recombination with a co-transfected plasmid. In an exemplary system, the essential El gene has been deleted from the viral vector, and the virus will not replicate unless the El gene is provided by the host cell the WO 99/01554 PCT/US98/13859 27 human 293 cell line). When intravenously administered to intact animals, adenovirus primarily targets the liver.

-If the adenoviral delivery system has an El gene deletion, the virus cannot replicate in the host cells. However, the host's tissue liver) will express and process (and, if a signal sequence is present, secrete) the heterologous protein. Secreted proteins will enter the circulation in the highly vascularized liver, and effects on the infected animal can be determined.

The adenovirus system can also be used for protein production in vitro. By culturing adenovirus-infected non-293 cells under conditions where the cells are not rapidly dividing, the cells can produce proteins for extended periods of time. For instance, BHK cells are grown to confluence in cell factories, then exposed to the adenoviral vector encoding the secreted protein of interest. The cells are then grown under serum-free conditions, which allows infected cells to survive for several weeks without significant cell division.

Alternatively, adenovirus vector infected 293S cells can be grown in suspension culture at relatively high cell density to produce significant amounts of protein (see A.

Garnier et al., Cytotechnol. 15:145-55 (1994). With either protocol, an expressed, secreted heterologous protein can be repeatedly isolated from the cell culture supernatant. Within the infected 293S cell production protocol, non-secreted proteins may also be effectively obtained.

PROTEIN ISOLATION: Expressed recombinant polypeptides (or chimeric polypeptides) can be purified using fractionation and/or conventional purification methods and media. Ammonium sulfate precipitation and acid or chaotrope extraction may WO 99/01554 PCT/US98/13859 28 be used for fractionation of samples. Exemplary purification steps may include hydroxyapatite, size exclusion, FPLC and reverse-phase high performance liquid chromatography. Suitable anion exchange media include derivatized dextrans, agarose, cellulose, polyacrylamide, specialty silicas, and the like. PEI, DEAE, QAE and Q derivatives are preferred, with DEAE Fast-Flow Sepharose (Pharmacia, Piscataway, NJ) being particularly preferred.

Exemplary chromatographic media include those media derivatized with phenyl, butyl, or octyl groups, such as Phenyl-Sepharose FF (Pharmacia), Toyopearl butyl 650 (Toso Haas, Montgomeryville, PA), Octyl-Sepharose.(Pharmacia) and the like; or polyacrylic resins, such as Amberchrom

CG

71 (Toso Haas) and the like. Suitable solid supports include glass beads, silica-based resins, cellulosic resins, agarose beads, cross-linked agarose beads, polystyrene beads, cross-linked polyacrylamide resins and the like that are insoluble under the conditions in which they are to be used. These supports may be modified with reactive groups that allow attachment of proteins by amino groups, carboxyl groups, sulfhydryl groups, hydroxyl groups and/or carbohydrate moieties. Examples of coupling chemistries include cyanogen bromide activation,

N-

hydroxysuccinimide activation, epoxide activation, sulfhydryl activation, hydrazide activation, and carboxyl and amino derivatives for carbodiimide coupling chemistries. These and other solid media are well known and widely used in the art, and are available from commercial suppliers. Methods for binding receptor polypeptides to support media are well known in the art.

Selection of a particular method is a matter of routine design and is determined in part by the properties of the chosen support. See, for example, Affinity Chromatography: Principles Methods, Pharmacia

LKB

Biotechnology, Uppsala, Sweden, (1988).

WO 99/01554 PCT/US98/13859 29 The polypeptides of the present invention can be isolated by exploitation of their properties. For example, immobilized metal ion adsorption (IMAC) chromatography can be used to purify histidine-rich proteins. Briefly, a gel is first charged with divalent metal ions to form a chelate, E. Sulkowski, Trends in Biochem. 3:1-7, (1985). Histidine-rich proteins will be adsorbed to this matrix with differing affinities, depending upon the metal ion used, and will be eluted by competitive elution, lowering the pH, or use of strong chelating agents. Other methods of purification include purification of glycosylated proteins by lectin affinity chromatography and ion exchange chromatography, Methods in Enzymol., Vol. 182, "Guide to Protein Purification", M.

Deutscher, Acad. Press, San Diego, (1990), pp.529- 39. Alternatively, a fusion of the polypeptide of interest and an affinity tag polyhistidine, maltose-binding protein, an immunoglobulin domain) may be constructed to facilitate purification.

Uses Overexpression of Zsig9 in tumor cells indicates that Zsig9 can be used as an indicator for cancer. Thus, antibodies of Zsig9 can be used as a diagnostic to determine the presence of Zsig9 and thus the presence of cancer as explained below. Furthermore, antibodies labeled with radioisotopes or fused with toxins can be used as a therapeutic to treat cancer. Anti-sense nucleotides derived from the Zsig9 cDNA can also be used as a therapeutic to inhibit the growth of tumor cells.

Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, WO 99/01554 PCT/US98/13859 inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic -molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant toxins (for instance, diphtheria toxin, Pseudomonas exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule may be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair.

In another embodiment, polypeptide-toxin fusion proteins or antibody/fragment-toxin fusion proteins may be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues).

Alternatively, if the polypeptide has multiple functional domains an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary molecule, the anticomplementary molecule may be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anticomplementary-detectable/ cytotoxic molecule conjugates.

WO 99/01554 PCT/US98/13859 31 In another embodiment, polypeptide-cytokine fusion proteins or antibody/fragment-cytokine fusion proteins may be used for enhancing in vitro cytotoxicity (for instance, that mediated by monoclonal antibodies against tumor targets) and for enhancing in vivo killing of target tissues (for example, blood and bone marrow cancers).

See, generally, J.L. Hornick et al., Blood 89:4437-47 (1997). In general, cytokines are toxic if administered systemically. The described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable Zsig9 polypeptides or anti-Zsig9 antibodies target an undesirable cell or tissue a tumor or a leukemia), and the fused cytokine mediates improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin 2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), for instance.

In yet another embodiment, if the Zsig9 polypeptide or anti-Zsig9 antibody targets vascular cells or tissues, such polypeptide or antibody may be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis. Such therapeutic approach poses less danger to clinicians who administer the radioactive therapy. For instance, iridium-192 impregnated ribbons placed into stented vessels of patients until the required radiation dose was delivered showed decreased tissue growth in the vessel and greater luminal diameter than the control group, which received placebo ribbons. Further, revascularisation and stent thrombosis were significantly lower in the treatment group. Similar results are predicted with targeting of a bioactive conjugate containing a radionuclide, as described herein.

WO 99/01554 PCTIUS98/13859 32 The bioactive polypeptide or antibody conjugates -described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.

USES OF POLYNUCLEOTIDE/POLYPEPTIDE: Molecules of the present invention can be used to identify and isolate receptors of Zsig9. For example, proteins and peptides of the present invention can be immobilized on a column and membrane preparations run over the column (Immobilized Affinity Ligand Techniques, Hermanson et al., eds., pp.195-202 (Academic Press, San Diego, CA, 1992). Proteins and peptides can also be radiolabeled (Methods in Enzymol., vol. 182: "Guide to Protein Purification", M. Deutscher, ed., 721-737 (Acad.

Press, San Diego, 1990,) or photoaffinity labeled (Brunner et al., Ann. Rev. Biochem. 62:483-514 (1993 and Fedan et al., Biochem. Pharmacol. 33:1167-1180 (1984) and specific cell-surface proteins can be identified.

Another aspect of the present invention involves antisense polynucleotide compositions that are complementary to a segment of the polynucleotides set forth in SEQ ID NOs: 1, 16 or 18. Such synthetic antisense oligonucleotides are designed to bind to mRNA encoding Zsig9 polypeptides and to inhibit translation of such mRNA. Such antisense oligonucleotides are used to inhibit expression of Zsig9 polypeptide-encoding genes in cell culture or in a subject.

The present invention also provides reagents which will find use in diagnostic applications. For example, the Zsig9 gene, a probe comprising Zsig9 DNA or RNA or a WO 99/01554 PCT/US98/13859 33 subsequence thereof can be used to determine if the zZsig9 gene is present on chromosome 12 or if a mutation has -occurred. Detectable chromosomal aberrations at the Zsig9 gene locus include, but are not limited to, aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements. Such aberrations can be detected using polynucleotides of the present invention by employing molecular genetic techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) analysis employing PCR techniques, and other genetic linkage analysis techniques known in the art (Sambrook et al., ibid.; Ausubel et. al., ibid.; A.J. Marian, Chest 108:255-65, 1995).

Transgenic mice, engineered to express the Zsig9 gene, and mice that exhibit a complete absence of Zsig9 gene function, referred to as "knockout mice", Snouwaert et al., Science 257:1083 (1992), may also be generated, Lowell et al., Nature 366:740-42 (1993). These mice may be employed to study the Zsig9 gene and the protein encoded thereby in an in vivo system.

CHROMOSOMAL LOCALIZATION: Radiation hybrid mapping is a somatic cell genetic technique developed for constructing high-resolution, contiguous maps of mammalian chromosomes, Cox et al., Science 250:245-50 (1990). Partial or full knowledge of a gene's sequence allows one to design PCR primers suitable for use with chromosomal radiation hybrid mapping panels.

Commercially available radiation hybrid mapping panels which cover the entire human genome, such as the Stanford G3 RH Panel and the GeneBridge 4 RH Panel (Research WO 99/01554 PCT/US98/13859 34 Genetics, Inc., Huntsville, AL), are available. These panels enable rapid, PCR-based chromosomal localizations -and ordering of genes, sequence-tagged sites (STSs), and other nonpolymorphic and polymorphic markers within a region of interest. This includes establishing directly proportional physical distances between newly discovered genes of interest and previously mapped markers. The precise knowledge of a gene's position can be useful for a number of purposes, including: 1) determining if a sequence is part of an existing contig and obtaining additional surrounding genetic sequences in various forms, such as YACs, BACs or cDNA clones; 2) providing a possible candidate gene for an inheritable disease which shows linkage to the same chromosomal region; and 3) cross-referencing model organisms, such as mouse, which may aid in determining what function a particular gene might have.

For pharmaceutical use, the proteins of the present invention are formulated for parenteral, particularly intravenous or subcutaneous, delivery according to conventional methods. Intravenous administration will be by bolus injection or infusion over a typical period of one to several hours. In general, pharmaceutical formulations will include a Zsig9 protein in combination with a pharmaceutically acceptable vehicle, such as saline, buffered saline, 5% dextrose in water or the like.

Formulations may further include one or more excipients, preservatives, solubilizers, buffering agents, albumin to prevent protein loss on vial surfaces, etc. Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, 19th Edition Gennaro, ed., (Mack Publishing Co., Easton PA, 1995). Therapeutic doses will generally be in the range of 0.1 to 100 Ig/kg of patient weight per day, preferably 0.5-20 lg/kg per day, with the exact dose determined by WO 99/01554 PCT/US98/13859 the clinician according to accepted standards, taking into account the nature and severity of the condition to be -treated, patient traits, etc. Determination of dose is within the level of ordinary skill in the art. The proteins may be administered for acute treatment, over one week or less, often over a period of one to three days or may be used in chronic treatment, over several months or years. In general, a therapeutically effective amount of Zsig9 is an amount sufficient to produce a clinically significant change in the liver, kidney, heart or placenta.

Zsiq9 Structure The potential N-terminal 3 dimensional structure of Zsig9 should have similarities to that predicted for amylin and calcitonin-gene related peptides (CGRP). Moving from the N-terminus to the C-terminus there is a predicted disulfide bond between residues 28 and 31 of SEQ ID NO:2.

This is like the predicted disulfide of amylin (positions 35-40) and CGRP1 and 2 (positions 84-89). If the mature form of Zsig9 is not cleaved at the Lys-Lys at position 48-49, there is probably a beta turn followed by an extended region with hydrophobic residues packing along the hydrophobic face of the helix. The C-terminus is probably not amidated as in amylin and CGRP if the mature form is cleaved at the Lys-Lys at position 48-49. If the mature form ends at either the serine at position 81 or at the phenylalanine at position 83, then the glycine at position 82 or the glycine at position 84 may be used to amidate the C-terminus.

WO 99/01554 PCT/US98/13859 36 Zsiq9 Tissue Distribution/Multiple mRNA sizes Northern analysis shows that Zsig9 is ubiquitous with higher levels in placenta, pancreas, thyroid, prostate, and liver. This may indicate that it is involved in homeostasis. Zsig9 is transcribed by many cell-types and is probably released by a variety of cell types in response to some metabolic stress. The Zsig9 receptor is then activated by Zsig9 to alleviate the stress. The stress may include non-optimal levels of sugar, carbohydrate, antigenic load, fat, temperature, pH, 02, osmotic concentration and the like.

Zsig9 is overexpressed in tumor cells. Thus, antibodies to Zsig9 can be used to diagnosis the presence of tumors. Radiolabeled antibodies to Zsig9 can further be used as an imaging agent to locate and treat tumors in the body. Anti-sense nucleotides to zsig9 can be used to inhibit the progression of tumors.

Therapeutic utility Cancer Diagnosis and Therapy As can be seen in Example 5, Zsig9 is overexpressed in a number of human tumors including brain, liver, lung, esophageal, stomach, colon, rectal, thyroid, and lymphoma tumors. Thus, antibodies to Zsig9 can be used both to detect and treat the tumors which overexpress Zsig9.

Radiolabeled antibodies to Zsig9 can used both to detect and localize tumors. Antibodies which are either radiolabeled or to which a toxic polypeptide is fused can also be used to treat tumors which overexpress Zsig9.

WO 99/01554 PCT/US98/13859 37 Nucleotide primers and probes of the Zsig9 gene can be used to detect the overexpression of Zsig9 using PCR.

Gene amplification of Zsig9 can be determined indirectly by assay of a patient body fluid to detect the presence of elevated levels of Zsig9. Suitable body fluids include serum and urine and exudates of the putative tumor tissues. Examples of immunoassays which can be used in determining the expression of Zsig9 to diagnose neoplastic diseases are described in the patent and scientific literature. See, for example U.S. Patent Nos. 3,791,932; 3,817,837; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; and 4,098,876. Antisense nucleotides to the Zsig9 DNA and RNA can be administered to a patient to inhibit expression of Zsig9 and thus inhibit tumor growth. Methods for Antibodies to the Zsig9 polypeptide can be purified and then administered to a patient. These reagents can be combined for therapeutic use with additional active or inert ingredients, in pharmaceutically acceptable carriers or diluents along with physiologically innocuous stabilizers and excipients. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies, binding fragments thereof or singlechain antibodies of the antibodies including forms which are not complement binding.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medications administered. Thus, treatment dosages should be titrated to optimize safety WO 99/01554 PCT/US98/13859 38 and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in vivo administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage.

Methods for administration include oral, intravenous, peritoneal, intramuscular, or transdermal administration.

Pharmaceutically acceptable carriers will include water, saline, buffers to name just a few. Dosage ranges would ordinarily be expected from lg to 1000 g per kilogram of body weight per day. However, the doses by be higher or lower as can be determined by a medical doctor with ordinary skill in the art. For a complete discussion of drug formulations and dosage ranges see Remington's Pharmaceutical Sciences,19 th Ed., (Mack Publishing Co., Easton, Penn., 1995), and Goodman and Gilman's: The Pharmacological Bases of Therapeutics,9 th Ed. (Pergamon Press 1996).

Nucleic Acid-based Therapeutic Treatment If a mammal has a mutated or lacks a Zsig9 gene, the Zsig9 gene can be introduced into the cells of the mammal.

In one embodiment, a gene encoding a Zsig9 polypeptide is introduced in vivo in a viral vector. Such vectors include an attenuated or defective DNA virus, such as but not limited to herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses which entirely or almost entirely lack viral genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but WO 99/01554 PCT/US98/13859 39 are not limited to, a defective herpes virus 1 (HSV1) vector [Kaplitt et al., Molec. Cell. Neurosci.,2 :320-330 an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al., J. Clin.

Invest., 90 :626-630 (1992), and a defective adenoassociated virus vector [Samulski et al., J. Virol., 61:3096-3101 (1987); Samulski et al. J. Virol., 63:3822- 3828 (1989)].

In another embodiment, the gene can be introduced in a retroviral vector, as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al., Cell, 33:153 (1983); Temin et al., U.S. Patent No. 4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., J.

Virol., 62:1120 (1988); Temin et al., U.S. Patent No.

5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995 by Dougherty et al.; and Blood, 82:845 (1993).

Alternatively, the vector can be introduced by lipofection in vivo using liposomes. Synthetic cationic lipids can be used to prepare liposomes for in vivo transfection of a gene encoding a marker [Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417 (1987); see Mackey et al., Proc. Natl. Acad. Sci. USA, 85:8027-8031 (1988)]. The use of lipofection to introduce exogenous genes into specific organs in vivo has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cells represents one area of benefit. It is clear that directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such 1.

WO 99/01554 PCT/US98/13859 as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules for the purpose of -targeting. Targeted peptides, hormones or neurotransmitters, and proteins such as antibodies, or non-peptide molecules could be coupled to liposomes chemically.

It is possible to remove the cells from the body and introduce the vector as a naked DNA plasmid and then reimplant the transformed cells into the body. Naked DNA vector for gene therapy can be introduced into the desired host cells by methods known in the art, e.g., transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter [see, Wu et al., J. Biol. Chem., 267:963-967 (1992); Wu et al., J. Biol. Chem., 263:14621- 14624 (1988)].

Zsig9 polypeptides can also be used to prepare antibodies that specifically bind to Zsig9 epitopes, peptides or polypeptides. The Zsig9 polypeptide or a fragment thereof is inoculate into an animal so as to elicit an immune response. Antibodies generated from this immune response can be isolated and purified as described herein. Methods for preparing and isolating polyclonal and monoclonal antibodies are well known in the art. See, for example, Current Protocols in Immunology, Cooligan, et al., Eds., (National Institutes of Health, John Wiley and Sons, Inc., 1995); Sambrook et al., Molecular Cloning:

A

Laboratory Manual, Second Edition, (Cold Spring Harbor, NY, 1989); and Hurrell, J. G. Ed., Monoclonal Hybridoma Antibodies: Techniques and Applications,

(CRC

Press, Inc., Boca Raton, FL, 1982).

WO 99/01554 PCT/US98/13859 41 As would be evident to one of ordinary skill in the art, polyclonal antibodies can be generated from inoculating a variety of warm-blooded animals such as horses, cows, goats, sheep, dogs, chickens, rabbits, mice, and rats with a Zsig9 polypeptide or a fragment thereof.

The immunogenicity of a Zsig9 polypeptide may be increased through the use of an adjuvant, such as alum (aluminum hydroxide) or Freund's complete or incomplete adjuvant.

Polypeptides useful for immunization also include fusion polypeptides, such as fusions of Zsig9 or a portion thereof with an immunoglobulin polypeptide or with maltose binding protein. The polypeptide immunogen may be a fulllength molecule or a portion thereof. If the polypeptide portion is "hapten-like", such portion may be advantageously joined or linked to a macromolecular carrier (such as keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) or tetanus toxoid) for immunization.

As used herein, the term "antibodies" includes polyclonal antibodies, affinity-purified polyclonal antibodies, monoclonal antibodies, and antigen-binding fragments, such as F(ab') 2 and Fab proteolytic fragments.

Genetically engineered intact antibodies or fragments, such as chimeric antibodies, Fv fragments, single chain antibodies and the like, as well as synthetic antigenbinding peptides and polypeptides, are also included.

Non-human antibodies may be humanized by grafting nonhuman CDRs onto human framework and constant regions, or by incorporating the entire non-human variable domains (optionally "cloaking" them with a human-like surface by replacement of exposed residues, wherein the result is a "veneered" antibody). In some instances, humanized antibodies may retain non-human residues within the human WO 99/01554 PCT/US98/13859 42 variable region framework domains to enhance proper binding characteristics. Through humanizing antibodies, biological half-life may be increased, and the potential for adverse immune reactions upon administration to humans is reduced.

Alternative techniques for generating or selecting antibodies useful herein include in vitro exposure of lymphocytes to Zsig9 protein or peptide, and selection of antibody display libraries in phage or similar vectors (for instance, through use pf immobilized or labeled Zsig9 protein or peptide). Genes encoding polypeptides having potential Zsig9 polypeptide binding domains can be obtained by screening random peptide libraries displayed on phage (phage display) or on bacteria, such as E. coli. Nucleotide sequences encoding the polypeptides can be obtained in a number of ways, such as through random mutagenesis and random polynucleotide synthesis. These random peptide display libraries can be used to screen for peptides which interact with a known target which can be a protein or polypeptide, such as a ligand or receptor, a biological or synthetic macromolecule, or organic or inorganic substances.

Techniques for creating and screening such random peptide display libraries are known in the art (Ladner et al., US Patent NO. 5,223,409; Ladner et al., US Patent NO.

4,946,778; Ladner et al., US Patent NO. 5,403,484 and Ladner et al., US Patent NO. 5,571,698) and random peptide display libraries and kits for screening such libraries are available commercially, for instance from Clontech (Palo Alto, CA), Invitrogen Inc. (San Diego, CA), New England Biolabs, Inc. (Beverly, MA) and Pharmacia

LKB

Biotechnology Inc. (Piscataway, NJ). Random peptide WO 99/01554 PCT/US98/13859 43 display libraries can be screened using the Zsig9 sequences disclosed herein to identify proteins which bind -to Zsig9. These "binding proteins" which interact with Zsig9 polypeptides can be used for tagging cells; for isolating homolog polypeptides by affinity purification; they can be directly or indirectly conjugated t6 drugs, toxins, radionuclides and the like. These binding proteins can also be used in analytical methods such as for screening expression libraries and neutralizing activity. The binding proteins can also be used for diagnostic assays for determining circulating levels of polypeptides; for detecting or quantitating soluble polypeptides as marker of underlying pathology or disease.

These binding proteins can also act as Zsig9 "antagonists" to block Zsig9 binding and signal transduction in vitro and in vivo. These anti-Zsig9 binding proteins would be useful for inhibiting the growth of tumors.

Antibodies are determined to be specifically binding if: 1) they exhibit a threshold level of binding activity, and/or 2) they do not significantly cross-react with related polypeptide molecules. First, antibodies herein specifically bind if they bind to a Zsig9 polypeptide, peptide or epitope with a binding affinity (Ka) of 106 M 1 or greater, preferably 107 M 1 or greater, more preferably 10 M 1 or greater, and most preferably M or greater. The binding affinity of an antibody can be readily determined by one of ordinary skill in the art, for example, by Scatchard analysis, Scatchard, G., Ann. NY Acad. Sci. 51: 660-672 (1949).

Second, antibodies are determined to specifically bind if they do not significantly cross-react with related polypeptides. Antibodies do not significantly cross-react WO 99/01554 PCT/US98/13859 44 with related polypeptide molecules, for example, if they detect Zsig9 but not known related polypeptides using a standard Western blot analysis (Ausubel et al., ibid.).

Examples of known related polypeptides are orthologs, proteins from the same species that are members of a protein family IL-16), Zsig9 polypeptides, and nonhuman Zsig9. Moreover, antibodies may be "screened against" known related polypeptides to isolate a population that specifically binds to the inventive polypeptides. For example, antibodies raised to Zsig9 are adsorbed to related polypeptides adhered to insoluble matrix; antibodies specific to Zsig9 will flow through the matrix under the proper buffer conditions. Such screening allows isolation of polyclonal and monoclonal antibodies non-crossreactive to closely related polypeptides, Antibodies: A Laboratory Manual, Harlow and Lane (eds.),(Cold Spring Harbor Laboratory Press, 1988); Current Protocols in Immunology, Cooligan, et al. (eds.), (National Institutes of Health, John Wiley and Sons, Inc., 1995). Screening and isolation of specific antibodies is well known in the art. See, Fundamental Immunology, Paul Eds., (Raven Press, 1993); Getzoff et al.,-Adv. in Immunol. 43: 1-98 (1988); Monoclonal Antibodies: Principles and Practice, Goding, Eds., (Academic Press Ltd., 1996); Benjamin et al., Ann. Rev. Immunol. 2: 67-101 (1984).

A variety of assays known to those skilled in the art can be utilized to detect antibodies which specifically bind to Zsig9 proteins or peptides. Exemplary assays are described in detail in Antibodies: A Laboratory Manual, Harlow and Lane, Eds., (Cold Spring Harbor Laboratory Press, 1988). Representative examples of such assays include: concurrent immunoelectrophoresis, WO 99/01554 PCT/US98/13859 radioimmunoassay, radioimmuno-precipitation, enzyme-linked immunosorbent assay (ELISA), dot blot or Western blot assay, inhibition or competition assay, and sandwich assay. In addition, antibodies can be screened for binding to wild-type versus mutant Zsig9 protein or polypeptide.

Antibodies to Zsig9 may be used for tagging cells that express Zsig9; for isolating Zsig9 by affinity purification; for diagnostic assays for determining circulating levels of Zsig9 polypeptides; for detecting or quantitating soluble Zsig9 as marker of underlying pathology or disease; in analytical methods employing FACS; for screening expression libraries; for generating anti-idiotypic antibodies; and as neutralizing antibodies or as antagonists to block Zsig9 in vitro and in vivo.

Suitable direct tags or labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like; indirect tags or labels may feature use of biotin-avidin or other complement/anti-complement pairs as intermediates. Antibodies herein may also b"e directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications. Moreover, antibodies to Zsig9 or fragments thereof may be used in vitro to detect denatured Zsig9 or fragments thereof in assays, for example, Western Blots or other assays known in the art.

Another embodiment of the present invention provides for a peptide or polypeptide comprising an epitope-bearing portion of a polypeptide of the invention. The epitope of the this polypeptide portion is an immunogenic or antigenic epitope of a polypeptide of the invention. A WO 99/01554 PCTIUS98/13859 46 region of a protein to which an antibody can bind is defined as an "antigenic epitope". See for instance, -Geysen, H.M. et al., Proc. Natl. Acad Sci. USA 81:3998- 4002 (1984).

As to the selection of peptides or polypeptides bearing an antigenic epitope that contain a region of a protein molecule to which an antibody can bind), it is well known in the art that relatively short synthetic peptides that mimic part of a protein sequence are routinely capable of eliciting an antiserum that reacts with the partially mimicked protein. See Sutcliffe,

J.G.

et al. Science 219:660-666 (1983). Peptides capable of eliciting protein-reactive sera are frequently represented in the primary sequence of a protein, can be characterized by a set of simple chemical rules, and are confined neither to immunodominant regions of intact proteins immunogenic epitopes) nor to the amino or carboxyl terminals. Peptides that are extremely hydrophobic and those of six or fewer residues generally are ineffective at inducing antibodies that bind to the mimicked protein; longer soluble peptides, especially those containing proline residues, usually are effective.

Antigenic epitope-bearing peptides and polypeptides of the invention are therefore useful to raise antibodies, including monoclonal antibodies, that bind specifically to a polypeptide of the invention.

Antigenic epitope-bearing peptides and polypeptides of the present invention contain a sequence of at least nine, preferably between 15 to about 30 amino acids contained within the amino acid sequence of a polypeptide of the invention. However, peptides or polypeptides comprising a larger portion of an amino acid sequence of the invention, containing from 30 to 50 amino acids, or any length up to WO 99/01554 PCT/US98/13859 47 and including the entire amino acid sequence of a polypeptide of the invention, also are useful for inducing -antibodies that react with the protein. Preferably, the amino acid sequence of the epitope-bearing peptide is selected to provide substantial solubility in aqueous solvents the sequence includes relatively hydrophilic residues and hydrophobic residues are preferably avoided); and sequences containing proline residues are particularly preferred. All of the polypeptides shown in the sequence listing contain antigenic epitopes to be used according to the present invention, however, specifically designed antigenic epitopes include the peptides defined by SEQ ID NO:24 BIOACTIVE CONJUGATES: Antibodies or polypeptides herein can also be directly or indirectly conjugated to drugs, toxins, radionuclides and the like, and these conjugates used for in vivo diagnostic or therapeutic applications. For instance, polypeptides or antibodies of the present invention can be used to identify or treat t-issues or organs that express a corresponding anti-complementary molecule (receptor or antigen, respectively, for instance). More specifically, Zsig9 polypeptides or anti- Zsig9 antibodies, or bioactive fragments or portions thereof, can be.coupled to detectable or cytotoxic molecules and delivered to a mammal having cells, tissues or organs that express the anti-complementary molecule.

Suitable detectable molecules may be directly or indirectly attached to the polypeptide or antibody, and include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent markers, chemiluminescent markers, magnetic particles and the like. Suitable cytotoxic WO 99/01554 PCT/US98/13859 48 molecules may be directly or indirectly attached to the polypeptide or antibody, and include bacterial or plant -toxins (for instance, diphtheria toxin, Pseudomona.s exotoxin, ricin, abrin and the like), as well as therapeutic radionuclides, such as iodine-131, rhenium-188 or yttrium-90 (either directly attached to the polypeptide or antibody, or indirectly attached through means of a chelating moiety, for instance). Polypeptides or antibodies may also be conjugated to cytotoxic drugs, such as adriamycin. For indirect attachment of a detectable or cytotoxic molecule, the detectable or cytotoxic molecule can be conjugated with a member of a complementary/ anticomplementary pair, where the other member is bound to the polypeptide or antibody portion. For these purposes, biotin/streptavidin is an exemplary complementary/ anticomplementary pair.

In another embodiment, polypeptide-toxin fusion proteins or antibody-toxin fusion proteins can be used for targeted cell or tissue inhibition or ablation (for instance, to treat cancer cells or tissues).

Alternatively, if the polypeptide has multiple functional domains an activation domain or a ligand binding domain, plus a targeting domain), a fusion protein including only the targeting domain may be suitable for directing a detectable molecule, a cytotoxic molecule or a complementary molecule to a cell or tissue type of interest. In instances where the domain only fusion protein includes a complementary molecule, the anticomplementary molecule can be conjugated to a detectable or cytotoxic molecule. Such domain-complementary molecule fusion proteins thus represent a generic targeting vehicle for cell/tissue-specific delivery of generic anticomplementary-detectable/ cytotoxic molecule conjugates.

WO 99/01554 PCT/US98/13859 49 In another embodiment, Zsig9-cytokine fusion proteins or antibody-cytokine fusion proteins can be used -for enhancing in vivo killing of target tissues (for example, blood and bone marrow cancers), if the Zsig9 polypeptide or anti-Zsig9 antibody targets the hyperproliferative blood or bone marrow cell (See, generally, Hornick et al., Blood 89:4437-47 (1997). They described fusion proteins enable targeting of a cytokine to a desired site of action, thereby providing an elevated local concentration of cytokine. Suitable Zsig9 polypeptides or anti-Zsig9 antibodies target an undesirable cell or tissue a tumor oi a leukemia), and the fused cytokine mediated improved target cell lysis by effector cells. Suitable cytokines for this purpose include interleukin-2 and granulocyte-macrophage colonystimulating factor (GM-CSF), for instance.

In yet another embodiment, if the Zsig9 polypeptide or anti- Zsig9 antibody targets vascular cells or tissues, such polypeptide or antibody may be conjugated with a radionuclide, and particularly with a beta-emitting radionuclide, to reduce restenosis or to reduce the growth of blood vessels in tumors. Such therapeutic approach poses less danger to clinicians who administer the radioactive therapy.

The bioactive polypeptide or antibody conjugates described herein can be delivered intravenously, intraarterially or intraductally, or may be introduced locally at the intended site of action.

USES OF POLYNUCLEOTIDE/POLYPEPTIDE: Molecules of the present invention can be used to identify and isolate receptors involved in the binding of Zsig9. For example, proteins and peptides of the WO 99/01554 PCT/US98/13859 present invention can be immobilized on a column and membrane preparations run over the column, Immobilized Affinity Ligand Techniques, Hermanson et al., eds., pp.195-202 (Academic Press, San Diego, CA, 1992).

Proteins and peptides can also be radiolabeled Methods in Enzymol., vol. 182, "Guide to Protein Purification",

M.

Deutscher, ed., p.p. 721-737 (Acad. Press, San Diego, 1990) or photoaffinity labeled, Brunner et al., Ann. Rev.

Biochem. 62:483-514 1993 and Fedan et al., Biochem.

Pharmacol. 33:1167-80 (1984) and specific cell-surface proteins can be identified.

GENE THERAPY: Polynucleotides encoding Zsig9 polypeptides are useful within gene therapy applications where it is desired to increase or inhibit Zsig9 activity. If a mammal has a mutated or absent Zsig9 gene, the Zsig9 gene can be introduced into the cells of the mammal. In one embodiment, a gene encoding a Zsig9 polypeptide is introduced in vivo in a viral vector. Such vectors include an attenuated or defective DNA virus, such as, but not limited to, herpes simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like. Defective viruses, which entirely or almost entirely lack viral genes, are preferred. A defective virus is not infective after introduction into a cell. Use of defective viral vectors allows for administration to cells in a specific, localized area, without concern that the vector can infect other cells. Examples of particular vectors include, but are not limited to, a defective herpes simplex virus 1 (HSV1) vector (Kaplitt et al., Molec. Cell. Neurosci.

2:320-30 (1991); an attenuated adenovirus vector, such as WO 99/01554 PCT/US98/13859 51 the vector described by Stratford-Perricaudet et al., J.

Clin. Invest. 90:626-30 (1992); and a defective adenoassociated virus vector, Samulski et al., J. Virol.

61:3096-101 (1987); Samulski et al., J. Virol. 63:3822-8 (1989).

In another embodiment, a Zsig9 gene can be introduced in a retroviral vector, as described in Anderson et al., U.S. Patent No. 5,399,346; Mann et al.

Cell 33:153 (1983); Temin et al., U.S. Patent No.

4,650,764; Temin et al., U.S. Patent No. 4,980,289; Markowitz et al., J. Virol. 62:1120 (1988); Temin et al., U.S. Patent No. 5,124,263; International Patent Publication No. WO 95/07358, published March 16, 1995 by Dougherty et al.; and Kuo et al., Blood 82:845 (1993).

Alternatively, the vector can be introduced by lipofection in vivo using liposomes. Synthetic cationic lipids can be used to prepare liposomes for in vivo transfection of a gene encoding a marker (Felgner et al., Proc. Natl. Acad.

Sci. USA 84:7413-7 (1987); Mackey et al., Proc. Natl.

Acad. Sci. USA 85:8027-31 (1988). The use of lipofection to introduce exogenous genes into specific organs in vivo has certain practical advantages. Molecular targeting of liposomes to specific cells represents one area of benefit. More particularly, directing transfection to particular cells represents one area of benefit. For instance, directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as the pancreas, liver, kidney, and brain. Lipids may be chemically coupled to other molecules for the purpose of targeting. Targeted peptides hormones or neurotransmitters), proteins such as antibodies, or non-peptide molecules can be coupled to liposomes chemically.

WO 99/01554 PCT/US98/13859 52 It is possible to remove the target cells from -the body; to introduce the vector as a naked DNA plasmid; and then to re-implant the transformed cells into the body. Naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun or use of a DNA vector transporter. See, Wu et al., J.

Biol. Chem. 267:963-7 (1992); Wu et al., J. Biol. Chem.

263:14621-4 (1988) Antisense methodology can be used to inhibit Zsig9 gene transcription, such as to inhibit cell proliferation in vivo. Polynucleotides that are complementary to a segment of a Zsig9-encoding polynucleotide a polynucleotide as set froth in SEQ ID NO:1) are designed to bind to Zsig9-encoding mRNA and to inhibit translation of such mRNA. Such antisense polynucleotides are used to inhibit expression of Zsig9 polypeptide-encoding genes in cell culture or in a subject.

The present invention also provides reagents which will find use in diagnostic applications. For example, the Zsig9 gene, a probe comprising Zsig9 DNA or RNA or a subsequence thereof can be used to determine if the Zsig9 gene is present on chromosome 12 or if a mutation has occurred. Detectable chromosomal aberrations at the Zsig9 gene locus include, but are not limited to, aneuploidy, gene copy number changes, insertions, deletions, restriction site changes and rearrangements.

Such aberrations can be detected using polynucleotides of the present invention by employing molecular genetic WO 99/01554 PCT/US98/13859 53 techniques, such as restriction fragment length polymorphism (RFLP) analysis, short tandem repeat (STR) -analysis employing PCR techniques, and other genetic linkage analysis techniques known in the art (Sambrook et al., ibid.; Ausubel et. al., ibid.; Marian, Chest 108:255-65 (1995).

The invention is further illustrated by the following non-limiting examples.

WO 99/01554 PCT/US98/13859 54 Example 1. Cloning of Zsiq9 Zsig9 was identified from expressed sequence tag (EST) SEQ ID NO: 7. The cDNA clone containing the EST was discovered in a placenta from a full-term pregnancy cDNA library which contained the EST. The cDNA was isolated from E. coli transfected with the plasmid and then streaked out on an LB 100 g/ml ampicillin and 100 pg/ml methicillin plate. The cDNA insert was sequenced. The insert was determined to be 649 base pairs long with a 84 amino acid open reading frame and a putative 20 amino acid signal peptide.

Example 2 Construction of Zsig9 Expression Vectors Two Zsig9 construction vectors were made in a flag amino acid sequence (SEQ ID NO: 8) was inserted onto the N-terminal or C-terminal ends of the Zsig9 polypeptide.

For the construction in which the flag amino acid sequence was attached to the N-terminus of Zsig9, a 473 bp Zsig9 PCR DNA fragment was generated with 1 gl of a dilution of the plasmid prep of Example 1 and 1 microliter (il) of SEQ ID NO: 9 and 10 each having a concentration of picomoles (pm)/il of primer. The PCR mixture contained il of 10X PCR buffer,0.5 KLENTAQ (both from CLONTECH), p. REDI-LOAD dye (Research Genetics), 2.5 nucleotide triphosphate mix (Perkin-Elmer) and 14 pl of water. The PCR reaction was incubated at 94 0 C for 5 minutes, and then run for 10 cycles each individual cycle being comprised of WO 99/01554 PCT/US98/13859 seconds at 94C and 2 minutes at 75 0 C. This was followed by 15 cycles each cycle being comprised of 30 seconds at 94 0 C and 2 minutes at 60 0 C. The reaction was ended with an incubation for 10 minutes at 74 0

C.

The resultant PCR mixture was then run on a 0.9% LMP agarose gel with TBE buffer. After the gel was run the band containing the DNA was cut out and the DNA was purified from the gel with a QUIAQUICK® column (Qiagen).

100 p1 of the DNA was digested in a solution containing 4 pl of B buffer, 1 pl of BamHl (Boehringer Mannheim) and 1 pl of Xhol (Boehringer Mannheim) for 2 hours at 37 0 C. The digested reaction mixture was electrophoresed on a 1% TBE gel; the DNA band was excised with a razor blade and the DNA was extracted from the gel with the Qiaquick® Gel Extraction Kit (Qiagen).

The excised DNA was subcloned into plasmid NF/pZP9 which had been cut with Bam and Xho. NF/pZP9 is a mammalian cell expression vector comprising an expression cassette containing the mouse metallothionein-1 promoter, a sequence encoding the tissue plasminogen activator (TPA) leader, then the flag peptide (SEQ ID NO:8), then multiple restriction sites. These were followed by the human growth hormone terminator, an E. coli origin of replication and a mammalian selectable marker expression unit containing the promoter, enhancer and origin of replication; a dihydrofolate reductase gene (DHFR) and the terminator. 1 p1 containing 10 ng of the NF/pZP9 vector which had been previously digested with Xho and BamHI was mixed with 1 p1 of 10X ligase buffer, 1 1l of T4 ligase and 2 pl of Zsig9 fragment containing 20 ng. The ligation took place at room temperature for 3 hours and then WO 99/01554 PCT/US98/13859 56 electroporated into DHO0b cells. After the electroporation the cells were plated onto LB-amp plates.

For the construction of the Zsig9 gene in which the flag polypeptide SEQ ID NO: 8 was inserted onto the Cterminus of the Zsig9 polypeptide, a 649 bp Zsig9 PCR fragment was generated with 1 pl of 1 dilution of the plasmid preparation containing Zsig9 described in Example 1 and 20 pm each of primers SEQ ID NO: 11 and SEQ ID NO: 12. The PCR reaction was incubated at 94C for 5 minutes, then run for 10 cycles, each cycle being comprised seconds at 94°C and 2 minutes at 75 0 C. This was followed by cycles each cycle comprised of 30 seconds at 94°C and 2 minutes at 60 0 C. The reaction was ended with a final minute extension at 74 0

C.

The entire reaction mixture was run on a 1% TBE gel and the DNA was cut out with a razor blade and the DNA was extracted using the QIAQUICKTM gel extraction kit. 20 1p out of the recovered 35 p1 digested with 10 units of BamHl (Boehringer Mannheim) and 10 units of EcoRl(Gibco BRL) for 2 hours at 370C. The digested PCR mixture was electrophoresed on a 1% TBE gel. The DNA band was cut out with a razor blade and the DNA was extracted from the gel using the QIAquick® Gel Extraction Kit (Qiagen). The extracted DNA was subcloned into plasmid CF/pZP9 which had been cut with EcoRl and BamHl. Plasmid cfpzp9 is a mammalian expression vector containing an expression cassette having the mouse metallothionein-1 promoter, multiple restriction sites for insertion of coding sequences, a sequence encoding the flag peptide, SEQ ID WO 99/01554 PCT/US98/13859 57 a stop codon, a human growth hormone terminator, an E. coli origin of replication, a mammalian selectable marker expression unit having an SV40 promoter, enhancer and origin of replication, a DHFR gene and the terminator.

Example 3 Tissue Distribution Human Multiple Tissue Northern Blots (MTN I, MTN II, and MTN III; Clontech) were probed to determine the tissue distribution of human ZSIG-9 expression. A 40 bp probe (SEQ ID NO: 13) was used to probe the blots.

The 5' end of the probe was radioactively labeled using T4 polynucleotide kinase and forward reaction buffer (GIBCO BRL, Gaithersburg, MD) according to the manufacturer's specifications. The probe was purified using a NUCTRAP push column (Stratagene, La Jolla, CA). ExpressHybTM (Clontech) solution was used for prehybridization and as a hybridizing solution for the Northern blots.- Hybridization took place overnight at 42 0 C using 2 x 106 cpm/ml of labeled probe. The blots were then washed at 55 0 C in 1X SSC, 0.1% SDS. A 1.2 kb transcript was detected. The signal was strongest in heart, placenta, liver and kidney. An intermediate signal was detected in spleen, thymus, prostate, testis, ovary, small intestine, colon, peripheral blood lymphocytes, thyroid, spinal cord.

Weak signal was detected in lymph node, trachea, adrenal gland and bone marrow.

WO 99/01554 PCT/US98/13859 58 EXAMPLE 4 Chromosomal Assignment and Placement of Zsig9.

Zsig9 was mapped to chromosome 12 using the commercially available "GeneBridge 4 Radiation Hybrid Panel" (Research Genetics, Inc., Huntsville, AL). The GeneBridge 4 Radiation Hybrid Panel contains PCRable DNAs from each of 93 radiation hybrid clones, plus two control DNAs (the HFL donor and the A23 recipient). A publicly available WWW server (http://www-genome.wi.mit.edu/cgibin/contig/rhmapper.pl) allows mapping relative to the Whitehead Institute/MIT Center for Genome Research's radiation hybrid map of the human genome (the "WICGR" radiation hybrid map) which was constructed with the GeneBridge 4 Radiation Hybrid Panel.

For the mapping of Zsig9 with the "GeneBridge 4 RH Panel", 20 pl reactions were set up in a PCRable 96-well microtiter plate (Stratagene, La Jolla, CA) and used in a "RoboCycler Gradient 96" thermal cycler (Stratagene). Each of the 95 PCR reactions consisted of 2 Al 10X KlenTaq PCR reaction buffer (CLONTECH Laboratories, Inc., Palo Alto, CA), 1.6 Al dNTPs mix (2.5 mM each, PERKIN-ELMER, Foster City, CA), 1 pA sense primer, SEQ ID NO: 14, 1 Al antisense primer, SEQ ID NO: 15, 2 l "RediLoad" (Research Genetics, Inc., Huntsville, AL), 0.4 Al Advantage KlenTaq Polymerase Mix (Clontech Laboratories, Inc.), 25 ng of DNA from an individual hybrid clone or control and x 1l ddH20 for a total volume of 20 Al. The reactions were overlaid with an equal amount of mineral oil and sealed. The PCR cycler conditions were as follows: an initial 1 cycle 5 minute denaturation at 95 0 C, 35 cycles of a 1 minute denaturation at 95 0 C, 1 minute annealing at 62 0 C and 1.5 minute extension at 72 0 C, followed by a final 1 cycle extension of 7 minutes at 72°C. The reactions were WO 99/01554 PCT/US98/13859 59 separated by electrophoresis on a 3% NuSieve GTG agarose gel (FMC Bioproducts, Rockland, ME).

The results showed that Zsig9 maps 344.72 cR 3000 from the top of the human chromosome 12 linkage group on the WICGR radiation hybrid map. Proximal and distal framework markers were WI-6672 (D12S1410) and RP L41 1, respectively. The use of the surrounding markers positions Zsig9 in the 12q15 region on the integrated LDB chromosome 12 map (The Genetic Location Database, University of Southhampton, WWW server: http://cedar.genetics.

soton.ac.uk/public html/) Example Northern Blot Analysis of Human Tumors Northern Analysis was carried out on the following Tumor Blots Human Tumor Panel Blot I, Human Tumor Panel Blot II, Human Tumor Panel Blot V, Human Stomach Tumor Blot, and Human Colon Tumor Blot (Clontech, Palo Alto, California). A probe was obtained using a PCR product representing the full length coding sequence of zsig9.

The probe was radioactively labeled with 32P using Rediprime Labeling System from Amersham (England).The probe was purified using a NUCTRAP push column(Stratagene Cloning Systems, La Jolla, Ca.) EXPRESSHYB (Clontech, Palo Alto, Ca.) solution was used for prehybridization and hybridization. The hybridization solution consisted of 8 mis EXPRESSHYB, 80 ul Sheared Salmon Sperm DNA (10mg/ml,5 Prime-3 Prime, Boulder, CO) 48 Jil Human Cot-1 DNA (img/ml, Gibco BRL) and 20 il labeled probe (8 x 10-5 CPM/ Hybridization took place overnight at 55 0 C And the blots were then washed in 2X SSC,0.1%SDS at RT, then 2X SSC,0.1% SDS at 60 0 C, followed by 0.1X SSC, 0.1% SDS wash at 60 0 C. The blots were exposed overnight and developed.

WO 99/01554 PCT/US98/13859 A transcript of .8-1kb was observed in the following -tissues. The strongest signals were in brain tumor, liver tumor, esophageal tumor, stomach tumor, colon tumor, rectal tumor, and thyroid tumor. Weaker signals were in adrenal tumor and normal adrenal, peratoid tumor, and lymphoma tumor. Weakest signals were observed in normal liver, normal esophagus, normal stomach, normal colon, normal rectum, normal thyroid, and normal lymphoma. The Stomach and Colon Tumor Blots showed signals consistent with those observed in the panel blots for stomach and colon tissue.

Example 6 Chromosomal Assignment and Placement of murine Zsig9 Murine Zsig9 was mapped in mouse to chromosome using the commercially available mouse T31 whole genome radiation hybrid (WGRH) panel (Research Genetics, Inc., Huntsville, AL) and the Map Manager QT linkage analysis program. At P 0.0001, murine Zsig9 linked proximal to D10Mitl36 at 62.0 cM with a LOD score of 4.3. This is a known region of synteny or linkage conservation with regions of human chromosome 12.

The T31 WGRH panel contains PCRable DNAs from each of 100 radiation hybrid clones, plus two control DNAs (the 129aa donor and the A23 recipient). For the mapping of murine Zsig9 with the T31 WGRH panel, 20 Al reactions were set up in PCRable 96-well microtiter plates (Stratagene, La Jolla, CA) and used in "RoboCycler Gradient 96" thermal cyclers (Stratagene). Each of the 102 PCR reactions consisted of 2 Al 10X KlenTaq PCR reaction buffer (CLONTECH Laboratories, Inc., Palo Alto, CA), 1.6 1l dNTPs mix (2.5 mM each, PERKIN-ELMER, Foster City, CA), 1 Al WO 99/01554 PCT/US98/13859 61 sense primer, (SEQ ID NO:22), 5' TCG CGC GAG AGT TTG GAG 1 il antisense primer, (SEQ ID NO:23), 5' CCC AGC TTC CCG CAC TTA 2 A1 "RediLoad" (Research Genetics, Inc., Huntsville, AL), 0.4 il 50X Advantage KlenTaq Polymerase Mix (Clontech Laboratories, Inc.), 25 ng of DNA from an individual hybrid clone or control and x Al ddH20 for a total volume of 20 Al. The reactions were overlaid with an equal amount of mineral oil and sealed. The PCR cycler conditions were as follows: an initial 1 cycle 5 minute denaturation at 94 0 C, 35 cycles of a 1 minute denaturation at 94 0 C, 1 minute annealing at 62 0 C and 1.5 minute extension at 72 0 C, followed by a final 1 cycle extension of 7 minutes at 72 0 C. The reactions were separated by electrophoresis on a 2% agarose gel (Life Technologies, Gaithersburg, MD). The use of the surrounding markers positions murine Zsig9 in the 51-62 centiMorgan (cM) region on mouse chromosome 10 map. Other genes of interest which lie in or near this region are glioma-associated oncogene homolog, myogenic factors 5 and 6, mast cell growth factor, insulin-like growth factor, and tumor rejection antigen-1.

EDITORIAL NOTE: 82866/98 The following sequence listing pages 1-16 are part of the description.

The claims begin on page 62 WO 99/01554 PCT/US98/13859 1 SEQUENCE LISTING GENERAL INFORMATION APPLICANT: ZymoGenetics, Inc.

1201 Eastlake Avenue East Seattle

WA

USA

98102 (ii) TITLE OF THE INVENTION: MAMMALIAN ZSIG9 (iii) NUMBER OF SEQUENCES: 24 (iv) CORRESPONDENCE ADDRESS: ADDRESSEE: ZymoGenetics Inc.

STREET: 1201 Eastlake Ave East CITY: Seattle STATE: WA COUNTRY: USA ZIP: 98102 COMPUTER READABLE FORM: MEDIUM TYPE: Diskette COMPUTER: IBM Compatible OPERATING SYSTEM: DOS SOFTWARE: FastSEQ for Windows Version (vi) CURRENT APPLICATION DATA: APPLICATION NUMBER: FILING DATE:

CLASSIFICATION:

(vii) PRIOR APPLICATION DATA: APPLICATION NUMBER: FILING DATE: (viii) ATTORNEY/AGENT INFORMATION: NAME: Lunn. Paul G WO 99/01554 PCT/US98/13859 2 REGISTRATION NUMBER: 32,743 REFERENCE/DOCKET NUMBER: 97-11PC (ix) TELECOMMUNICATION INFORMATION: TELEPHONE: 206-442-6627 TELEFAX: 206-442-6678

TELEX:

INFORMATION FOR SEQ ID NO:1: SEQUENCE CHARACTERISTICS: LENGTH: 649 base pairs TYPE: nucleic acid STRANDEDNESS: double TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: Coding Sequence LOCATION: 104...354 OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: CGGCCCAAGG CTGGGGCCAA AGTGAAAGTC GCGGCCCTGG GACCAAAGGT GGAGCAACCC

CAGCGGTCTN

CGTTACCCTA

CCAGCGCTTG GGCCACGGCG AAR ATG AAA GGC TGG Met Lys Gly Trp 1 115 GGT TGG CTG Gly Trp Leu GCC CTG CTT CTG GGG GCC CTG CTG GGA ACC GCC TGG GCT Ala Leu Leu Leu Gly Ala Leu Leu Gly Thr Ala Trp Ala 10 15 CGG AGG Arg Arg AGC CAG GAT Ser Gin Asp CTC CAC TGT GGA GCA TGC AGG GCT CTG GTG GAT Leu His Cys Gly Ala Cys Arg Ala Leu Val Asp 30 163 211 259 GAA CTA GAA TGG Glu Leu Glu Trp GAA ATT GCC CAG GTG GAC CCC AAG AAG ACC ATT CAG Glu Ile Ala Gln Val Asp Pro Lys Lys Thr Ile Gln 45 WO 99/01554 PCT/US98/13859 ATG GGA TCT Met Gly Ser GTA ACT GTT Val Thr Val TTC CGG ATC AAT CCA Phe Arg Ile Asn Pro 60 ACT GTT CCC CCA AAC Thr Val Pro Pro Asn 75 GAT GGC AGC CAG TCA GTG GTG GAG Asp Gly Ser Gin Ser Val Val Glu AAA GTA GCT CAC TCT GGC TTT GG AT Lys Val Ala His Ser Gly Phe Gly 307 356

GAAATTCGAT

AAAAGATTTG

TCCTGGCTGC

CCTGATCAGC

CATGCAAACA

TGCTTAAAAA

GCTCTGTCTC

AAACCTTAAT

ACCCTTNTCC

TTCCGTTCAA

GGACCTTGGT

ATTTGGAAGA

ACTTTGTTTN

ACATCCACAT

AATCTGAGTC

TTAATAGAAA

AGCTGCAGGC

TGCTGTAGAA

GACTGGTTTT

GGAGCTAAAA

TGAAGAAAAC

TTATTCCCCA

TTTGTTAGCA

TAATGTAGCA

AAAAAAAAAA

AGACTCAGAA

TGCACTTGCT

AACAGGGAGT

CTGTGGTATA

AAA

416 476 536 596 649 INFORMATION FOR SEQ ID NO:2: SEQUENCE CHARACTERISTICS: LENGTH: 84 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met 1 Thr Ala Lys Gly Trp Ala Trp Ala Leu Val Asp Gly 5 Trp Leu Ala Leu Leu 10 Leu Leu Gly Ala Leu Leu Gly Arg Arg Ser Gin Asp 25 Glu His Cys Gly Ala Cys Arg Asp Pro Lys Glu Leu Glu Lys Thr lle Gin Met Gly Ser Val Ser 55 Val Trp 40 Phe Thr Ile Ala Gin Val Glu Val Val Asp Arg Ile Asn Pro Val Pro Pro Asn Gly Ser Gin Ser Thr 70 Lys Val Ala Gly Phe Gly INFORMATION FOR SEQ ID NO:3: SEQUENCE CHARACTERISTICS: LENGTH: 64 amino acids TYPE: amino acid WO 99/01554 PCT/US98/13859 STRANDEDNESS: single TOPOLOGY: linear Arg 1 Glu Met Val Ser 1 Glu Ser Val (xi) SEQUENCE DESCRIPTION: SEQ ID N Arg Ser Gin Asp Leu His Cys Gly Ala C 5 10 Leu Glu Trp Glu Ile Ala Gin Val Asp P 25 Gly Ser Phe Arg Ile Asn Pro Asp Gly S 40 Thr Val Thr Val Pro Pro Asn Lys Val A 55 INFORMATION FOR SEQ ID NO:4: SEQUENCE CHARACTERISTICS: LENGTH: 62 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID N G1n Asp Leu His Cys Gly Ala Cys Arg A 5 10 Trp Glu Ile Ala Gln Val Asp Pro Lys L 25 Phe Arg Ile Asn Pro Asp Gly Ser Gln S 40 Thr Val Pro Pro Asn Lys Val Ala His Si 55 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 25 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: peptide 0:3: ys Arg Ala Leu Val Asp ro Lys Lys Thr Ile Gin er Gin Ser Val Val Glu la His Ser Gly Phe Gly D:4: la Leu Val Asp Glu Leu ys Thr Ile Gin Met Gly er Val Val Glu Val Thr er Gly Phe Gly WO 99/01554 PCT/US98/13859 (xi) SEQUENCE DESCRIPTION: SEQ ID Ser Gin Asp Leu His Cys Gly Ala Cys Arg Ala Leu Val Asp Glu Leu 10 1 Glu Trp Glu Ile Ala Gin Val Asp Pro INFORMATION FOR SEQ ID NO:6: SEQUENCE CHARACTERISTICS: LENGTH: 35 amino acids TYPE: amino acid STRANDEDNESS: single.

TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Thr Ile Gin Met Gly Ser Phe Arg Ile 1 5 Val Val Glu Val Thr Val Thr Val Pro 25 Gly Phe Gly Pro Asp Gly Ser Gin Ser Ala His Ser Pro Asn Lys Val INFORMATION FOR SEQ ID NO:7: SEQUENCE CHARACTERISTICS: LENGTH: 417 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (vi) ORIGINAL SOURCE: ORGANISM: EST192508 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

CTGGGGCAAA

GCAGAGGTGG

TCTGGGGGCC

ATGCAGGGCT

CATTCAGATG

GTGAGAGTCC

AGCGACCCCA

CTGCTGGGAA

CTGGTGGATG

GGATCTTTCC

AGCGGTCTTC

TTACGCTAAA

CCGCCTGGGC

AACTAGAATG

GGATCAATCC

CAGCGCTTGG

GATGAAAGGC

TCGGAGGAGC

GGAAATTGCC

AGATGGCAGC

GCCACGGCGG

TGGGGTTGGC

AGGGATCTCC

CAGGTGGACC

CAGTCAGTGG

CGGCCTGGGA

TGGCCCTGCT

ACTGTGGAGC

CCAAGAAGAC

TNGAGGTAAC

120 180 240 300 WO 99/01554 PCT/US98/13859 6 TGTTACTGTT CCCCCAAACA AAGTAGCTCA CTCTGGCTTT NGATGAATTT CGATTTNTTT 360 AAAAAGGACC TTTGTTTTAT TAGGAATTGA AGAAAACAGA TTCAGAAAAA AGTTT 417 INFORMATION FOR SEQ ID NO:8: SEQUENCE CHARACTERISTICS: LENGTH: 10 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (vi) ORIGINAL SOURCE: ORGANISM: Flag (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Asp Tyr Lys Asp Asp Asp Asp Lys Gly Ser 1 5 INFORMATION FOR SEQ ID NO:9: SEQUENCE CHARACTERISTICS: LENGTH: 25 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (vi) ORIGINAL SOURCE: ORGANISM: zc13654 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: GCGCGGATCC CGGAGGAGCC AGGAT INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 25 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (iv) ANTISENSE: YES WO 99/01554 PCT/US98/13859 7 (vi) ORIGINAL SOURCE: ORGANISM: ZC13.655 (xi) SEQUENCE DESCRIPTION: SEQ ID CGCGCTCGAG TCATCCAAAG CCAGA INFORMATION FOR SEQ ID NO:11: SEQUENCE CHARACTERISTICS: LENGTH: 25 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: Other (vi) ORIGINAL SOURCE: ORGANISM: ZC13656 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: GCGCGAATTC ATGAAAGGCT GGGGT INFORMATION FOR SEQ ID NO:12: SEQUENCE CHARACTERISTICS: LENGTH: 25 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (iv) ANTISENSE: YES (vi) ORIGINAL SOURCE: ORGANISM: ZC13657 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: CGCGGGATCC TCCAAAGCCA GAGTG INFORMATION FOR SEQ ID NO:13: SEQUENCE CHARACTERISTICS: LENGTH: 40 base pairs TYPE: nucleic acid STRANDEDNESS: single WO 99/01554 PCT/US98/13859 8 TOPOLOGY: linear (iv) ANTISENSE: YES (vi) ORIGINAL SOURCE: ORGANISM: ZC11.666 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: TTCATCCACC AGAGCCCTGC ATGCTCCACA GTGGAGATCC INFORMATION FOR SEQ ID NO:14: SEQUENCE CHARACTERISTICS: LENGTH: 18 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (vi) ORIGINAL SOURCE: ORGANISM: zc 14,477 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: GGGCTCTGGT GGATGAAC 18 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 18 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (iv) ANTISENSE: YES (vi) ORIGINAL SOURCE: ORGANISM: ZC 14.489 (xi) SEQUENCE DESCRIPTION: SEQ ID TACCTCCACC ACTGACTG 18 INFORMATION FOR SEQ ID NO:16: SEQUENCE CHARACTERISTICS: LENGTH: 806 base pairs WO 99/01554 PCT/US98/13859 9 TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: NAME/KEY: Coding Sequence LOCATION: 104...649 OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: CGGCCCAAGG CTGGGGCCAA AGTGAAAGTC CAGCGGTCTN CCAGCGCTTG GGCCACGGCG GCGGCCCTGG GACCAAAGGT GGAGCAACCC CGTTACCCTA AAR ATG AAA GGC TGG Met Lys Gly Trp 1

GGT

Gly TGG CTG GCC CTG CTT Trp Leu Ala Leu Leu 10 CTG GGG GCC CTG CTG Leu Gly Ala Leu Leu 15 CAC TGT GGA GCA TGC His Cys Gly Ala Cys 30 GGA ACC GCC TGG GCT Gly Thr Ala Trp Ala AGG GCT CTG GTG GAT Arg Ala Leu Val Asp CGG AGG AGC CAG GAT Arg Arg Ser Gin Asp GAA CTA GAA TGG GAA Glu Leu Glu Trp Glu ATG GGA TCT TTC CGG Met Gly Ser Phe Arg 163 211 259 307 ATT GCC CAG GTG Ile Ala Gin Val 45 ATC AAT CCA GAT Ile Asn Pro Asp 60 GAC CCC AAG AAG ACC ATT CAG Asp Pro Lys Lys Thr Ile Gin GGC AGC CAG TCA GTG GTG GAG Gly Ser Gln Ser Val Val Glu GTG CCT Val Pro TAT GCC CGC TCA GAG Tyr Ala Arg Ser Glu 75 GCC CAC CTC ACA GAG CTG CTG GAG GAG Ala His Leu Thr Glu Leu Leu Glu Glu 355

ATA

Ile TGT GAC CGG ATG AAG Cys Asp Arg Met Lys 90 GAG TAT GGG GAA CAG Glu Tyr Gly Glu Gln 95 CGT GTA GTG GGC CGG Arg Val Val Gly Arg 110 ATT GAT CCT TCC ACC Ile Asp Pro Ser Thr 100 AAT GGA GAA TCC AGT Asn Gly Glu Ser Ser 115 403 451 CAT CGC AAG AAC TAC His Arg Lys Asn Tyr 105 WO 99/01554 PCT/US98/13859 GAA CTG GAC CTA Gl.u Leu Asp Leu 120 CAA GGC ATC CGA ATC Gin Gly Ile Arg Ile 125 GAC TCA GAT ATT AGC GGC ACC Asp Ser Asp Ile Ser Gly Thr 130 499 CTC AAG TTT GCG TGT GAG AGC ATT Leu Lys Phe Ala Cys Glu Ser Ile 135 140 GTG GAG GAA TAC GAG GAT GAA CTC Val Glu Glu Tyr Glu Asp Glu Leu 145 547 595 ATT GAA Ile Glu 150 TTC TTT TCC CGA GAG GCT GAC AAT GTT AAA GAC AAA CTT TGC Phe Phe Ser Arg Glu Ala Asp Asn Val Lys Asp Lys Leu Cys 155 160 AGT AAG CGA ACA GAT CTT Ser Lys Arg Thr Asp Leu 165 170 TGT GAC .CAT Cys Asp His

GCC

Ala CAC ATA TCG CAT GAT His Ile Ser His Asp 180 643 GAG CTA TGAACCACTG GAGCAGCCCA CACTGGCTTG ATGGATCACC CCCAGGAGGG GA Glu Leu AAATGGTGGC AATGCCTTTT ATATATTATG TTTTTACTGA AACCAAAAGT AAAAAAAAA AAAAAAAGAG AGAGAGAGAG

AATTAACTGA

AACTA

AAAAATATGA 761 806 INFORMATION FOR SEQ ID NO:17: SEQUENCE CHARACTERISTICS: LENGTH: 182 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly Ala Leu 1 5 10 Thr Ala Trp Ala Arg Arg Ser Gin Asp Leu 25 Ala Leu Val Asp Glu Leu Glu Trp Glu lle 40 Lys Thr Ile Gin Met Gly Ser Phe Arg Ile 55 Leu Gly His Cys Gly Ala Gin Val Asn Pro Asp Ala Cys Arg Asp Pro Lys Gly Ser G1n WO 99/01554 PCT/US98/13859 Ser Leu Val Val Glu Val Pro 70 Tyr Ala Arg Ser Glu 75 Ala His Leu Thr Glu Leu Glu Glu Cys Asp Arg Met Lys Val Glu Tyr Gly Glu Gin Ile Asp Pro Ser Thr Arg Lys Asn Tyr 105 Gln Arg Val Val Gly Glu Ser 115 Ile Ser Gly Glu Leu Asp Gly Ile Arg Ile 125 Val Gly Arg Asn 110 Asp Ser Asp Glu Glu Tyr Thr Leu Lys 130 G1u Asp Phe 135 Phe Cys Glu Ser Glu Leu Ile Phe Ser Arg 145 Asp Glu 155 Cys Asp Asn Val Lys Leu Cys Arg Thr Asp Asp His Ala Leu 175 Ile Ser His Asp Glu Leu 180 INFORMATION FOR SEQ ID NO:18: SEQUENCE CHARACTERISTICS: LENGTH: 1069 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) (ix) MOLECULE TYPE: cDNA

FEATURE:

NAME/KEY: Coding Sequence LOCATION: 358...903 OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GAATTCGGCA

GCGAGAGTTT

CAGATCTCCG

CCCTGAACCT

GCCAGCTGCT

CCTGGGCCAC

CGAGGGGGGT

GGAGGGGCGG

CTTAGGTGCC

GGCGGGAGCC

AGGGTTGGGA

GGCGGCGGCC

CCTCGCTGCC

GCTTAGGGTC

TAGTTAAGTG

GGAGCGCTCT

CCCACAGAAA

GTGGGAGCAG

TCGGAGGCGC

AGTTTCGGTG

CGGGAAGCTG

GGAGAAGCCG

ACAAAGTGAG

AGGTGGAGCG

TCCTAAAGCT

GGGGGCTCGC

GGCCAGGCGG

GGACAGCCCC

AGTCCGGCTG

ACCCTGTTAC

GCCTGCTCGC

ACGGGACCCT

TCACTGGCCA

GTTTTTCCCA

CTTTCCAGAG

ACTAAAG ATG Met 120 180 240 300 360 WO 99/01554 PCT/US98/13859 AAA GGC TGG GGT TGG CTA GCC CTA Lys Gly Trp Gly Trp Leu Ala Leu CTT TTG GGG GTC CTG CTG GGA ACT Leu Leu Gly Val Leu Leu Gly Thr 10 CTA CAC TGT GGA GCT TGC AGG GCT Leu His Cys Gly Ala Cys Arg Ala GCC TGG GCT CGA AGG AGC Ala Trp Ala Arg Arg Ser CAA GAT Gln Asp 25 408 456 504 CTG GTG Leu Val GAT GAA TTA GAG TGG Asp Glu Leu Glu Trp 40 GAA ATT GCC CGC GTG GAC CCC AAG AAG Glu Ile Ala Arg Val Asp Pro Lys Lys ATT CAG ATG GGA TCC Ile Gln Met Gly Ser TTC CGA ATC AAT CCA Phe Arg Ile Asn Pro 60 GCC CGC TCA GAG GCC Ala Arg Ser Glu Ala 75 GAT GGC AGC CAG TCA Asp Gly Ser Gin Ser CAC CTC ACA GAG TTG His Leu Thr Glu Leu GTT GTG GAG GTA CCT Val Val Glu Val Pro CTT GAG GAG GTG TGT Leu Glu Glu Val Cys CCT TCT ACC CAC CGC Pro Ser Thr His Arg 100 552 600 648 696 GAC CGA ATG AAG Asp Arg Met Lys 90 AAG AAC TAC GTA Lys Asn Tyr Val 105 GAG TAC GGG GAA CAG ATT GAC Glu Tyr Gly Glu Gin Ile Asp CGC GTC GTG AGC CGG AAT GGA Arg Val Val Ser Arg Asn Gly 110 GAA TCC Glu Ser 115 AGT GAA CTA GAC TTA CAG Ser Glu Leu Asp Leu Gin 120 GGC ATC CGA ATT GAC TCA GAT ATC Gly Ile Arg Ile Asp Ser Asp Ile 125 GGC ACC CTC AAG TTT Gly Thr Leu Lys Phe 135 GCG TGT GAG AGC ATT GTG Ala Cys Glu Ser Ile Val 140 GAA GAA TAC GAG Glu Glu Tyr Glu 145 GAT GAG CTT ATC GAA Asp Glu Leu Ile Glu 150 AAA CTT TGC AGT AAG Lys Leu Cys Ser Lys 165 TTC TTC TCC AGA GAG Phe Phe Ser Arg Glu 155 CGG ACA GAT CTA TGT Arg Thr Asp Leu Cys 170 GCT GAC AAC GTT AAA GAC Ala Asp Asn Val Lys Asp 160 GAC CAT GCC CTG CAC AGA Asp His Ala Leu His Arg 175 792 840 888 WO 99/01554 PCT/US98/13859 13 TCT CAC GAT GAG CTA TGAATCACTG GAGCAAGCAG CCTACACCAA ACGTGATGGA A 944 Ser His Asp Glu Leu 180 CACCCCCAGG AGGGGAAGAT GGCAGCATTG CCTTTTATAT TACGTTTTTA TGGAAATGAA 1004 CTGAAAAAA CTCTTGAAAC CGAAAGTAAA AAAAAAAAAA AAAAAAAAAA AATTTCCGCG 1064 GCCGC 1069 INFORMATION FOR SEQ ID NO:19: SEQUENCE CHARACTERISTICS: LENGTH: 182 amino acids TYPE: amino acid STRANDEDNESS: single.

TOPOLOGY: linear (ii) MOLECULE TYPE: protein FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Met Lys Gly Trp Gly Trp Leu Ala Leu Leu Leu Gly Val Leu Leu Gly 1 5 10 Thr Ala Trp Ala Arg Arg Ser Gin Asp Leu His Cys Gly Ala Cys Arg 25 Ala Leu Val Asp Glu Leu Glu Trp Glu Ile Ala Arg Val Asp Pro Lys 40 Lys Thr Ile Gln Met Gly Ser Phe Arg Ile Asn Pro Asp Gly Ser Gin 55 Ser Val Val Glu Val Pro Tyr Ala Arg Ser Glu Ala His Leu Thr Glu 70 75 Leu Leu Glu Glu Val Cys Asp Arg Met Lys Glu Tyr Gly Glu Gin Ile 90 Asp Pro Ser Thr His Arg Lys Asn Tyr Val Arg Val Val Ser Arg Asn 100 105 110 Gly Glu Ser Ser Glu Leu Asp Leu Gln Gly Ile Arg Ile Asp Ser Asp 115 120 125 Ile Ser Gly Thr Leu Lys Phe Ala Cys Glu Ser Ile Val Glu Glu Tyr 130 135 140 Glu Asp Glu Leu Ile Glu Phe Phe Ser Arg Glu Ala Asp Asn Val Lys 145 150 155 160 Asp Lys Leu Cys Ser Lys Arg Thr Asp Leu Cys Asp His Ala Leu His 165 170 175 Arg Ser His Asp Glu Leu 180 WO 99/01554 14 INFORMATION FOR SEQ ID SEQUENCE CHARACTERISTICS: LENGTH: 162 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID PCT/US98/13859 Arg Arg Ser Gln Asp 1 Glu Met Val Ile His Glu Leu Ile Ser 145 Glu Leu Gly Pro Cys Arg Leu Lys Glu 130 Lys Leu Glu Ser Tyr Asp Lys Asp Phe 115 Phe Arg Trp Phe Ala Arg Asn Leu 100 Ala Phe Thr Leu Ile Ile Ser Lys 70 Val Gly Glu Arg Leu 150 Cys Gln Pro 40 Ala Tyr Val Arg Ile 120 Ala Asp Gly Val 25 Asp His Gly Val Ile 105 Val Asp His Ala 10 Asp Gly Leu Glu Gly Asp Glu Asn Ala Arg Lys G1n Glu Ile Asn Asp Tyr Lys 140 His Ala Lys Ser Leu Asp Gly Ile Glu 125 Asp Ile Leu Thr Val Leu Pro Glu Ser 110 Asp Lys Ser Val Ile Val Glu Ser Ser Gly Glu Leu His Asp Gin Glu Glu Thr Ser Thr Leu Cys Asp 160 INFORMATION FOR SEQ ID NO:21: SEQUENCE CHARACTERISTICS: LENGTH: 162 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: protein WO 99/01554 PCT/US98/13859 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: Arg Arg Ser Gin Asp 1 Glu Met Val Val His Glu Leu Ile Ser 145 Glu Glu Ser Tyr Asp Lys Asp Phe 115 Phe Arg 5 Glu Arg Arg Met Tyr Gln Cys Ser Asp Leu Ile Ile Ser Lys 70 Val Gly Glu Arg Leu 150 His Ala Asn Glu Glu Arg Ile Ser Glu 135 Cys Arg Pro 40 Ala Tyr Val Arg Ile 120 Ala Asp Cys Gly Ala Cys Arg Ala Leu Val Asp Asp Gly Leu Glu Ser Asp Glu Asn Al a Lys G1n Glu Ile Asn Asp Tyr Lys 140 His Lys Ser Leu Asp Gly Ile Glu 125 Asp Arg Gln Glu Glu Thr Ser Thr Leu Cys Asp 160 INFORMATION FOR SEQ ID NO:22: SEQUENCE CHARACTERISTICS: LENGTH: 18 base pairs TYPE: nucleic acid STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: Other (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: TCGCGCGAGA GTTTGGAG INFORMATION FOR SEQ ID NO:23: SEQUENCE CHARACTERISTICS: LENGTH: 18 base pairs TYPE: nucleic acid WO 99/01554 PCT/US98/13859 16 STRANDEDNESS: single TOPOLOGY: linear (ii) MOLECULE TYPE: Other (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CCCAGCTTCC CGCACTTA INFORMATION FOR SEQ ID NO:24: SEQUENCE CHARACTERISTICS: LENGTH: 35 amino acids TYPE: amino acid STRANDEDNESS: single TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Arg Arg Ser Gln Asp Leu His Cys Gly Ala Cys Arg Ala 1 5 10 Glu Leu Glu Trp Glu Ile Ala Gln Val Asp 25 Met Gly Ser Leu Val Asp Thr Ile Gin Pro Lys Lys

Claims

1. An isolated polynucleotide which encodes a mammalian polypeptide selected from the group consisting of SEQ ID NOs:17, 19, 20 and 21 or a polypeptide which is at least 90% identical to the polypeptides of said group.

2. An expression vector comprising the following operably linked elements: a transcription promoter; a polynucleotide which encodes a mammalian polypeptide selected from the group consisting of SEQ ID Nos:17, 19, 20 and 21 or a polypeptide which is at least identical to the polypeptides of said group; and 0t a transcription terminator.

3. An expression vector comprising a polynucleotide which encodes a mammalian polypeptide selected from the group consisting of SEQ ID Nos:17, 19, 20 and 21 or a polypeptide which is at least 90% identical to the polypeptides of said group, substantially as hereinbefore described with reference to any one of the examples. 15 4. A host cell into which has been introduced an expression vector according to claim 2 or 3.

5. The host cell of claim 4 which is a eukaryotic host cell.

6. A method of producing a mammalian polypeptide selected from the group consisting of SEQ ID Nos:17, 19, 20 and 21 or a polypeptide which is at least identical to the polypeptides of said group, the method comprising culturing the host cell of claim 4 or 5 under conditions conducive to expression of said polypeptide and isolating said expressed polypeptide.

7. A mammalian polypeptide selected from the group consisting of SEQ ID Nos: 17, 19, 20 and 21 or a polypeptide which is at least 90% identical to the polypeptides of said group produced according to the method of claim 6.

8. An isolated polypeptide selected from the group of amino acid sequences consisting of SEQ ID NOs:2-6 or a polypeptide which is at least 90% identical to said polypeptides.

9. An isolated polypeptide selected from the group of amino acid sequences consisting of SEQ ID NOs:17, 20, 19 and 21 or a polypeptide which is at least identical to said polypeptides. A pharmaceutical composition comprising a polypeptide according to any one of claims 7 to 9 together with a pharmaceutically acceptable vehicle.

11. A chimeric polypeptide consisting essentially of a first portion and a second portion joined by a peptide bound, the first portion consisting essentially of a Zsig9 [R:\LIBZZ]04193.doc:mIT 63 polypeptide as shown in SEQ ID NOs:2-6, 17, 20, 19 and 21 allelic variants of SEQ ID NOs:2-6, 17, 20 19 and 21; and protein polypeptides that are at least 90% identical to or the second portion comprising an affinity tag.

12. The chimeric polypeptide of claim 11, wherein said affinity tag is an immunoglobulin Fc polypeptide.

13. An isolated antibody, antibody fragment or single-chain antibody that specifically binds to a mammalian polypeptide, said polypeptide being defined by the amino acid sequences of SEQ ID NOs:2-6.

14. An isolated antibody, antibody fragment or single-chain antibody that specifically binds to a mammalian polypeptide, said polypeptide being defined by the amino acid sequences of SEQ ID NOs:17, 20, 19 and 21. An isolated antibody of claim 13 or 14, wherein said antibody is either monoclonal or polyclonal.

16. The antibody, antibody fragment or single-chain antibody of any one of S i5 claims 13 to 15, wherein said antibody, antibody fragment or single-chain antibody is S. humanized. S 4 17. A pharmaceutical composition comprising an antibody, antibody fiagment or single-chain antibody according to any one of claims 13 to 16, together with a pharmaceutically acceptable vehicle. 20 18. The use of an antibody, antibody fragment or single chain antibody according to any one of claims 13 to 16 to produce an anti-idiotypic antibody.

19. An anti-idiotypic antibody produced according to claim 18.

20. A pharmaceutical composition comprising an anti-idiotypic antibody of claim 19 together with a pharmaceutically acceptable carrier.

21. A method for producing an antibody which binds to a mammalian polypeptide or a peptide or polypeptide defined by SEQ ID NOs:2-6 or to a peptide or polypeptide which is at least 90% identical to said peptide or polypeptide comprising bringing into contact a polypeptide defined by SEQ ID NOs:2-6 or a peptide or polypeptide which is at least 90% identical to said peptide or polypeptide with a cell capable of producing antibodies or the cell is brought into contact with a nucleic acid which encodes said peptide or polypeptide, wherein said cell produces antibodies to said peptide or polypeptide; and isolating said antibody. S22. A method for producing an antibody which binds to a polypeptide defined by SEQ ID NOs:17, 19, 20 or 21 or to a peptide or polypeptide which is at least [R:\LIBZZ]04193.doc:mrr 4 64 identical to said peptide or polypeptide comprising bringing into contact a polypeptide defined by SEQ ID NOs:17, 20, 19 and 21 or a peptide or polypeptide which is at least identical to said peptide or polypeptide with a cell capable of producing antibodies or the cell is brought into contact with a nucleic acid which encodes said peptide or polypeptide, wherein said cell produces antibodies to said peptide or polypeptide; and isolating said antibody.

23. The method of claim 21 or 22, wherein an animal is inoculated with the peptide or polypeptide or nucleic acid under conditions wherein the animal produces antibodies to said peptide; and isolating said antibodies.

24. The method of any one of claims 21 to 23, wherein the antibodies are polyclonal or monoclonal. An antibody produced by the method according to any one of claims 21 to 24.

26. A pharmaceutical composition comprising the antibody of claim 25 together with a pharmaceutically acceptable vehicle. 15 Dated 9 October, 2001 ZymoGenetics, Inc. •O S 0* 0 0 Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON •lSSS [R:\LIBZZ]04193.doc:mrr